# **Supporting Information**

## Direct visible-light-induced synthesis of P-stereogenic phosphine oxides

### under air conditions

Ying Zhang,<sup>‡</sup><sup>a</sup> Jia Yuan,<sup>‡</sup><sup>b</sup> Guanglong Huang,<sup>c</sup> Hong Yu,<sup>a</sup> Jinpeng Liu,<sup>a</sup> Jian Chen,<sup>a</sup> Sixuan Meng,<sup>a</sup> Jian-Ji Zhong,<sup>c</sup> Li Dang,<sup>\*c</sup> Guang-Ao Yu,<sup>\*a</sup> and Chi-Ming Che<sup>\*bc</sup>

#### **Table of Contents**

1. General considerations	S2
2. General procedures for visible-light-promoted phosphinylation of heteroaryl halides under air	S2
3. X-ray Structural Determination	S14
4. Computational Methods	S15
5. References	
\$33	
6. <sup>1</sup> H, <sup>13</sup> C, <sup>19</sup> F and <sup>31</sup> P NMR spectra for all products	S34
7. HPLC spectra for all products	S85

#### 1. General considerations

All chemical reagents were purchased from Alfa-Aesar and J&K Scientific Ltd. (*R*)-*tert*-butyl(phenyl)phosphine oxide, (±)-methyl(phenyl)phosphine oxide and (±)-cyclohexyl(phenyl)phosphine oxide were synthesized according to the published procedures. <sup>1</sup> Chira Resolution – Semi-Prep HPLC (chiracel AD-H column, 15% 2-Propanol in Hexane, 5 ml/min) – (*S*)-[cyclohexyl(phenyl)phosphine oxide] t = 8.304 min, (*R*)-[cyclohexyl(phenyl)phosphine oxide] t = 9.542 min. Utilizing a 10 x 250 mm column with stacked injections of variable sizes (50 mg/ml concentration), we have been able to resolve up to 100 mg of racemic monomer in a 4 hour period.

The <sup>1</sup>H, <sup>13</sup>C, <sup>19</sup>F and <sup>31</sup>P NMR spectroscopic data were recorded on Bruker Mercury Plus 400 MHz NMR spectrometers. Chemical shifts ( $\delta$ ) for <sup>1</sup>H and <sup>13</sup>C are referenced to internal solvent resonances and reported relative to SiMe<sub>4</sub>. Chemical shifts for <sup>19</sup>F are reported relative to an external CFCl<sub>3</sub> standard. Chemical shifts for <sup>31</sup>P are reported relative to an external 85% H<sub>3</sub>PO<sub>4</sub> standard. High resolution mass analysis is performed on Varian 7.0T Fourier-transform mass spectrometry with ESI resource. High performance liquid chromatography (HPLC) was performed on DIONEX Ultimate 3000 series chromatographs using a Daicel Chiracel *AD*-H (4.6 mm Ø x 250 mm) or *OJ*-H (4.6 mm Ø x 250 mm) or *AS*-H (4.6 mm Ø x 250 mm) column with *n*-hexane/*i*-PrOH as an eluent. UV-vis absorption spectrum was recorded on a Hewlett-Packard 8453 diode array spectrophotometer.



Scheme S1. Synthesis of optically pure (R)-tert-butyl(phenyl)phosphine oxide [1]

#### 2. General procedures for visible-light-promoted phosphinylation of heteroaryl halides under air

To a round bottom flask, heteroaryl halides (0.6 mmol), (*R*)-*tert*-butyl(phenyl)phosphine oxide (0.5 mmol), NaOH (0.75mmol) and DMSO (2.5 mL) were added. The mixture was stirred at room temperature under 7 W blue LED irradiation. After stirring for 6 h, the reaction mixture was quenched with 10 mL of water and extracted with 10 mL of  $CH_2Cl_2$  three times. The combined organic fractions were dried by  $MgSO_4$ , filtered and concentrated via rotary evaporation. The crude product was purified by chromatograph on silica gel (dichloromethane/acetone).



(*R*)-*tert*-butyl(phenyl)(pyridin-2-yl)phosphine oxide (4): Performed according to the general procedure to afford 109 mg (84%) of **4** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.72 (d, *J* = 4.4 Hz, 1 H, Ar), 8.19–8.12 (m, 3 H, Ar), 7.75–7.68 (m, 1 H, Ar), 7.43–7.33 (m, 3 H, Ar), 7.32–7.27 (m, 1 H, Ar), 1.14 (d, *J* = 15.1 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  156.7 (d, *J*<sub>C-P</sub> = 117.2 Hz, Ar), 149.2 (d, *J*<sub>C-P</sub> = 17.6 Hz, Ar), 135.9 (d, *J*<sub>C-P</sub> = 8.5 Hz, Ar), 132.7 (d, *J*<sub>C-P</sub> = 7.6 Hz, Ar), 131.3 (d, *J*<sub>C-P</sub> = 2.5 Hz, Ar), 130.0 (d, *J*<sub>C-P</sub> = 89.6 Hz, Ar), 129.2 (s, Ar), 129.0 (s, Ar), 127.8 (s, Ar), 127.7 (s, Ar), 124.9 (d, *J*<sub>C-P</sub> = 2.9 Hz, Ar), 33.8 (d, *J*<sub>C-P</sub> = 69.6 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.6 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  32.6 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>15</sub>H<sub>19</sub>NOP: 260.1199, found: 260.1197. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 90/10, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 12.392 min (minor) and t<sub>R2</sub> = 13.512 min (major), ee = 98%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +73.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(6-methylpyridin-2-yl)(phenyl)phosphine oxide (5): Performed according to the general procedure to afford 117 mg (86%) of **5** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.28–8.21 (m, 2 H, Ar), 8.06–8.01 (m, 1 H, Ar), 7.70–7.64 (m, 1 H, Ar), 7.50–7.41 (m, 3 H, Ar), 7.22 (d, *J* = 7.9 Hz, 1 H, Ar), 2.66 (s, 3 H, *CH*<sub>3</sub>), 1.22 (d, *J* = 15.1 Hz, 9 H, C(*CH*<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  158.1 (d, *J*<sub>C-P</sub> = 17.6 Hz, Ar), 155.8 (d, *J*<sub>C-P</sub> = 118.7 Hz, Ar), 136.1 (d, *J*<sub>C-P</sub> = 9.0 Hz, Ar), 132.8 (d, *J*<sub>C-P</sub> = 7.5 Hz, Ar), 131.3 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 130.2 (d, *J*<sub>C-P</sub> = 89.2 Hz, Ar), 127.7 (d, *J*<sub>C-P</sub> = 10.9 Hz, Ar), 126.3 (s, Ar), 126.1 (s, Ar), 124.7 (d, *J*<sub>C-P</sub> = 3.1 Hz, Ar), 33.8 (d, *J*<sub>C-P</sub> = 69.6 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.7 (s, *C*(*C*H<sub>3</sub>)<sub>3</sub>), 24.6 (s, *C*H<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  32.0 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>21</sub>NOP: 274.1355, found: 274.1353. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 5.965 min (major) and t<sub>R2</sub> = 6.979 min (minor), ee = 97%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +13.0 (c = 1.0 in CHCl<sub>3</sub>).

(*R*)-*tert*-butyl(5-methylpyridin-2-yl)(phenyl)phosphine oxide (6): Performed according to the general procedure to afford 108 mg (79%) of **6** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.64 (s, 1 H, Ar), 8.30–8.18 (m, 2 H, Ar), 8.16–8.10 (m, 1 H, Ar), 7.61 (d, *J* = 7.8 Hz, 1 H, Ar), 7.51–7.41 (m, 3 H, Ar), 2.39 (s, 3 H, *CH*<sub>3</sub>), 1.21 (d, *J* = 15.1 Hz, 9 H, C(*CH*<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  153.4 (d, *J*<sub>C-P</sub> = 119.8 Hz, Ar), 150.1 (d, *J*<sub>C-P</sub> = 18.1 Hz, Ar), 136.3 (d, *J*<sub>C-P</sub> = 9.0 Hz, Ar), 135.0 (d, *J*<sub>C-P</sub> = 3.1 Hz, Ar), 132.8 (d, *J*<sub>C-P</sub> = 7.6 Hz, Ar), 131.3 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 130.3 (d, *J*<sub>C-P</sub> = 89.6 Hz, Ar), 128.9 (s, Ar), 128.7 (s, Ar), 127.8 (d, *J*<sub>C-P</sub> = 10.9 Hz, Ar), 33.8 (d, *J*<sub>C-P</sub> = 69.8 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.6 (s, C(CH<sub>3</sub>)<sub>3</sub>), 18.6 (d, *J*<sub>C-P</sub> = 1.4 Hz, *C*H<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  32.9 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>21</sub>NOP: 274.1355, found: 274.1352. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 11.099 min (major) and t<sub>R2</sub> = 22.752 min (minor), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +133.0 (c = 1.0 in CHCl<sub>3</sub>).

(*R*)-*tert*-butyl(4-methylpyridin-2-yl)(phenyl)phosphine oxide (7): Performed according to the general procedure to afford 107 mg (78%) of **7** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.68–8.62 (m, 1 H, Ar), 8.22 (t, *J* = 8.1 Hz, 2 H, Ar), 8.10 (d, *J* = 2.9 Hz, 1 H, Ar), 7.50–7.41 (m, 3 H, Ar), 7.19 (s, 1 H, Ar), 2.38 (d, *J* = 2.5 Hz, 3 H, *CH*<sub>3</sub>), 1.27–1.20 (m, 9 H, C(*CH*<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  156.2 (d, *J*<sub>C-P</sub> = 117.3 Hz, Ar), 149.2 (d, *J*<sub>C-P</sub> = 18.5 Hz, Ar), 147.3 (d, *J*<sub>C-P</sub> = 8.7 Hz, Ar), 132.7 (d, *J*<sub>C-P</sub> = 7.6 Hz, Ar), 131.3 (d, *J*<sub>C-P</sub> = 2.4 Hz, Ar), 130.2 (d, *J*<sub>C-P</sub> = 89.4 Hz, Ar), 130.0 (d, *J*<sub>C-P</sub> = 17.0 Hz, Ar), 127.7 (d, *J*<sub>C-P</sub> = 10.9 Hz, Ar), 125.8 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 33.8 (d, *J*<sub>C-P</sub> = 69.6 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.6 (s, *C*(*C*H<sub>3</sub>)<sub>3</sub>), 21.0 (s, *C*H<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  32.9 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>21</sub>NOP: 274.1355, found: 274.1351. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 98/2, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 42.386 min (minor) and t<sub>R2</sub> = 45.219 min (major), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +25.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(3-methylpyridin-2-yl)(phenyl)phosphine oxide (8): Performed according to the general procedure to afford 43 mg (32%) of **8** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.58 (s, 1 H, Ar), 7.91 (t, *J* = 8.3 Hz, 2 H, Ar), 7.48 (d, *J* = 4.8 Hz, 2 H, Ar), 7.43 (d, *J* = 7.4 Hz, 2 H, Ar), 7.27 (d, *J* = 2.6 Hz, 1 H, Ar), 2.51 (s, 3 H, CH<sub>3</sub>), 1.36–1.30 (m, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  154.3 (d, *J*<sub>C-P</sub> = 120.7 Hz, Ar), 145.5 (d, *J*<sub>C-P</sub> = 18.6 Hz, Ar), 140.9 (d, *J*<sub>C-P</sub> = 18.4 Hz, Ar), 139.3 (d, *J*<sub>C-P</sub> = 8.0 Hz, Ar), 132.7 (d, *J*<sub>C-P</sub> = 8.0 Hz, Ar), 131.3 (d, *J*<sub>C-P</sub> = 86.7 Hz, Ar), 131.2 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 127.8 (d, *J*<sub>C-P</sub> = 10.8 Hz, Ar), 124.8 (d, *J*<sub>C-P</sub> = 3.1 Hz, Ar), 35.0 (d, *J*<sub>C-P</sub> = 71.1 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 25.0 (s, C(CH<sub>3</sub>)<sub>3</sub>), 19.3 (s, CH<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  38.7 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>21</sub>NOP: 274.1355, found: 274.1354. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 4.832 min (major) and t<sub>R2</sub> = 5.279 min (minor), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +52.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(6-methoxypyridin-2-yl)(phenyl)phosphine oxide (9): Performed according to the general procedure to afford 124 mg (86%) of **9** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.25–8.18 (m, 2 H, Ar), 7.84 (t, *J* = 6.5 Hz, 1 H, Ar), 7.72–7.65 (m, 1 H, Ar), 7.52–7.42 (m, 3 H, Ar), 6.91–6.81 (m, 1 H, Ar), 4.05 (s, 3 H, OCH<sub>3</sub>), 1.25 (d, *J* = 15.1 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  163.2 (d, *J*<sub>C-P</sub> = 18.0 Hz, Ar), 153.0 (d, *J*<sub>C-P</sub> = 117.8 Hz, Ar), 138.5 (d, *J*<sub>C-P</sub> = 10.0 Hz, Ar), 132.5 (d, *J*<sub>C-P</sub> = 7.6 Hz, Ar), 131.4 (d, *J*<sub>C-P</sub> = 2.5 Hz, Ar), 130.1 (d, *J*<sub>C-P</sub> = 89.8 Hz, Ar), 127.8 (d, *J*<sub>C-P</sub> = 10.9 Hz, Ar), 123.1 (d, *J*<sub>C-P</sub> = 16.4 Hz, Ar), 113.4 (d, *J*<sub>C-P</sub> = 2.5 Hz, Ar), 53.9 (s, OCH<sub>3</sub>), 33.7 (d, *J*<sub>C-P</sub> = 69.9 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), <sup>24.6</sup> (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  32.9 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>21</sub>NO<sub>2</sub>P: 290.1304, found: 290.1303. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 5.652 min (major) and t<sub>R2</sub> = 6.192 min (minor), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +56.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(phenyl)(4-phenylpyridin-2-yl)phosphine oxide (12): Performed according to the general procedure to afford 70 mg (42%) of 12 as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.80–8.75 (m, 1 H, Ar), 8.46–8.41 (m, 1 H, Ar), 8.19 (t, *J* = 8.6 Hz, 2 H, Ar), 7.64 (d, *J* = 6.7 Hz, 2 H, Ar), 7.54 (d, *J* = 2.1 Hz, 1 H, Ar), 7.44–7.36 (m, 6 H, Ar), 1.22–1.60 (m, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  156.2 (d, *J*<sub>C-P</sub> = 116.7 Hz, Ar), 148.8 (d, *J*<sub>C-P</sub> = 18.3 Hz, Ar), 147.3 (d, *J*<sub>C-P</sub> = 8.7 Hz, Ar), 136.3 (s, Ar), 131.8 (d, *J*<sub>C-P</sub> = 7.6 Hz, Ar), 130.4 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 129.0 (d, *J*<sub>C-P</sub> = 89.7 Hz, Ar), 128.4 (s, Ar), 128.1 (s, Ar), 126.8 (d, *J*<sub>C-P</sub> = 11.0 Hz, Ar), 126.1 (s, Ar), 125.9 (d, *J*<sub>C-P</sub> = 17.5 Hz, Ar), 121.5 (d, *J*<sub>C-P</sub> = 3.0 Hz, Ar), 32.9 (d, *J*<sub>C-P</sub> = 69.5 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 23.7 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  33.2 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>21</sub>H<sub>23</sub>NOP: 336.1512, found: 336.1508. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 9.312 min (minor) and t<sub>R2</sub> = 19.099 min (major), ee = 98%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = -86.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(6-fluoropyridin-2-yl)(phenyl)phosphine oxide (13): Performed according to the general procedure to afford 120 mg (87%) of 13 as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.23–8.15 (m, 3 H, Ar), 7.82–7.75 (m, 1 H, Ar), 7.54–7.40 (m, 4 H, Ar), 1.23 (d, *J* = 15.4 Hz, 9 H, C(*CH*<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 157.4 (d, *J*<sub>C-F</sub> = 113.3 Hz, Ar), 151.1 (d, *J*<sub>C-P</sub> = 19.0 Hz, Ar), 138.7 (d, *J*<sub>C-P</sub> = 8.7 Hz, Ar), 132.7 (d, *J*<sub>C-P</sub> = 7.7 Hz, Ar), 131.7 (d, *J*<sub>C-P</sub> = 2.8 Hz, Ar), 129.2 (d, *J*<sub>C-P</sub> = 90.7 Hz, Ar), 128.1 (s, Ar), 128.0 (s, Ar), 127.8 (d, *J*<sub>C-P</sub> = 15.8 Hz, Ar), 126.0 (d, *J*<sub>C-P</sub> = 2.6 Hz, Ar), 34.0 (d, *J*<sub>C-P</sub> = 69.9 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.5 (s, C(*C*H<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 32.4 (s). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ - 65.5 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>15</sub>H<sub>18</sub>FNOP: 278.1105, found: 278.1105. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 7.739 min (major) and t<sub>R2</sub> = 8.505 min (minor), ee = 99%. [α]<sub>D</sub><sup>20</sup> = +87.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(6-chloropyridin-2-yl)(phenyl)phosphine oxide (14): Performed according to the general procedure to afford 100 mg (68%) of 14 as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.23–8.15 (m, 3 H, Ar), 7.81–7.75 (m, 1 H, Ar), 7.55–7.45 (m, 3 H, Ar), 7.42 (d, *J* = 8.1 Hz, 1 H, Ar), 1.23 (d, *J* = 15.4 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  157.5 (d, *J*<sub>C-P</sub> = 113.2 Hz, Ar), 151.1 (d, *J*<sub>C-P</sub> = 18.7 Hz, Ar), 138.7 (d, *J*<sub>C-P</sub> = 8.7 Hz, Ar), 132.7 (d, *J*<sub>C-P</sub> = 7.7 Hz, Ar), 131.7 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 129.3 (d, *J*<sub>C-P</sub> = 90.6 Hz, Ar), 128.1 (s, Ar), 128.0 (s, Ar), 127.9 (s, Ar), 127.8 (s, Ar), 126.0 (d, *J*<sub>C-P</sub> = 2.5 Hz, Ar), 34.0 (d, *J*<sub>C-P</sub> = 69.9 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.6 (s, C(CH<sub>3</sub>)<sub>3</sub>) <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  32.3 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>15</sub>H<sub>18</sub>CINOP: 294.0809, found: 294.0808. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 5.925 min (major) and t<sub>R2</sub> = 6.412 min (minor), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +283.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(phenyl)(5-(trifluoromethyl)pyridin-2-yl)phosphine oxide (15): Performed according to the general procedure to afford 67 mg (41%) of 15 as yellow solid <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.02 (s, 1 H, Ar), 8.37–8.32 (m, 1 H, Ar), 8.14–8.09 (m, 2 H, Ar), 8.00 (d, *J* = 8.1 Hz, 1 H, Ar), 7.47–7.38 (m, 3 H, Ar), 1.17 (d, *J* = 15.4 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  161.91 (d, *J*<sub>C-P</sub> = 1.3 Hz, Ar), 160.80 (d, *J*<sub>C-P</sub> = 1.3 Hz, Ar), 146.08 (m, Ar), 145.91 (m, Ar), 133.11 (m, Ar), 132.74 (d, *J*<sub>C-P</sub> = 7.8 Hz, Ar), 131.81 (d, *J*<sub>C-P</sub> = 2.8 Hz, Ar), 128.94 (m, Ar), 128.04 (d, *J*<sub>C-P</sub> = 11.1 Hz, Ar), 127.73 (d, *J*<sub>C-P</sub> = 2.9 Hz, Ar), 123.2 (q, *J*<sub>C-F</sub> = 272.7Hz, *C*F<sub>3</sub>), 34.08 (d, *J*<sub>C-P</sub> = 69.7 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.5 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  -62.7 (s). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  33.0 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>18</sub>F<sub>3</sub>NOP: 328.1073, found: 328.1071. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 90/10, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 7.925 min (major) and t<sub>R2</sub> = 22.659 min (minor), ee = 97%. [ $\alpha$ ]<sub>D<sup>20</sup></sub> = +36.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(phenyl)(pyridin-3-yl)phosphine oxide (16): Performed according to the general procedure to afford 95 mg (73%) of 16 as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.06 (s, 1 H, Ar), 8.68 (s, 1 H, Ar), 8.28–8.21 (m, 1 H, Ar), 7.90–7.83 (m, 2 H, Ar), 7.50–7.42 (m, 3 H, Ar), 7.40–7.35 (m, 1 H, Ar), 1.19 (d, *J* = 15.3 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  152.1 (d, *J*<sub>C-P</sub> = 1.6 Hz, Ar), 152.0 (d, *J*<sub>C-P</sub> = 9.9 Hz, Ar), 140.4 (d, *J*<sub>C-P</sub> = 5.9 Hz, Ar), 132.1 (s), 132.0 (s), 131.9 (s), 130.6 (s, Ar), 129.7 (s, Ar), 128.6 (s, Ar), 128.5 (s, Ar), 123.5 (d, *J*<sub>C-P</sub> = 6.3 Hz, Ar), 34.1 (d, *J*<sub>C-P</sub> = 71.4 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 25.0 (s, *C*(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  37.3 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>15</sub>H<sub>19</sub>NOP: 260.1199, found: 260.1198. HPLC analysis of the product: Daicel Chiralpak OJ-H column; *n*-hexane/*i*-PrOH = 95/05, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 11.859 min (minor) and t<sub>R2</sub> = 13.179 min (major), ee = 98%. [ $\alpha$ ]<sub>p</sub><sup>20</sup> = -21.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(6-methylpyridin-3-yl)(phenyl)phosphine oxide (17): Performed according to the general procedure to afford 82 mg (60%) of 17 as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.05–8.97 (m, 1 H, Ar), 8.24–8.14 (m, 1 H, Ar), 7.96–7.87 (m, 2 H, Ar), 7.56–7.47 (m, 3 H, Ar), 7.29 (s, 1 H, Ar), 2.62 (s, 3 H, CH<sub>3</sub>), 1.25 (d, *J* = 15.3 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  161.6 (d, *J*<sub>C-P</sub> = 1.9 Hz, Ar), 151.6 (d, *J*<sub>C-P</sub> = 10.1 Hz, Ar), 140.6 (d, *J*<sub>C-P</sub> = 6.4 Hz, Ar), 132.0 (d, *J*<sub>C-P</sub> = 8.3 Hz, Ar), 131.8 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 130.4 (d, *J*<sub>C-P</sub> = 91.8 Hz, Ar), 128.4 (d, *J*<sub>C-P</sub> = 11.1 Hz, Ar), 124.3 (d, *J*<sub>C-P</sub> = 88.4 Hz, Ar), 123.2 (d, *J*<sub>C-P</sub> = 8.3 Hz, Ar), 34.1 (d, *J*<sub>C-P</sub> = 71.7 Hz, C(CH<sub>3</sub>)<sub>3</sub>), 24.9 (s, C(CH<sub>3</sub>)<sub>3</sub>), 24.6 (d, *J*<sub>C-P</sub> = 1.5 Hz, CH<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  37.7 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>21</sub>NOP: 274.1355, found: 274.1354. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 17.125 min (minor) and t<sub>R2</sub> = 17.919 min (major), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +20.0 (c = 1.0 in CHCl<sub>3</sub>).

(*R*)-*tert*-butyl(2,6-dimethylpyridin-4-yl)(phenyl)phosphine oxide (18): Performed according to the general procedure to afford 72 mg (50%) of **18** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.99–7.90 (m, 2 H, Ar), 7.57–7.45 (m, 5 H, Ar), 2.59 (s, 6 H, CH<sub>3</sub>), 1.26 (d, *J* = 15.2 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  157.9 (d, *J*<sub>C-P</sub> = 9.2 Hz, Ar), 141.0 (d, *J*<sub>C-P</sub> = 82.8 Hz, Ar), 131.9 (t, *J*<sub>C-P</sub> = 6.3 Hz, Ar), 129.9 (d, *J*<sub>C-P</sub> = 91.3 Hz, Ar), 128.4 (d, *J*<sub>C-P</sub> = 11.0 Hz, Ar), 122.4 (d, *J*<sub>C-P</sub> = 6.6 Hz, Ar), 33.9 (d, *J*<sub>C-P</sub> = 70.3 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 25.0 (s, C(CH<sub>3</sub>)<sub>3</sub>), 24.6 (s, CH<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  37.3 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>23</sub>NOP: 288.1512, found: 288.1510. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 5.639 min (major) and t<sub>R2</sub> = 7.379 min (minor), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +13.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(phenyl)(quinolin-2-yl)phosphine oxide (19): Performed according to the general procedure to afford 113 mg (73%) of 19 as yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.36–8.21 (m, 5 H, Ar), 7.86–7.74 (m, 2 H, Ar), 7.60 (t, *J* = 7.5 Hz, 1 H, Ar), 7.50–7.40 (m, 3 H, Ar), 1.30 (d, *J* = 15.2 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  157.5 (d, *J*<sub>C-P</sub> = 116.4 Hz, Ar), 147.7 (d, *J*<sub>C-P</sub> = 19.9 Hz, Ar), 135.8 (d, *J*<sub>C-P</sub> = 8.3 Hz, Ar), 132.9 (d, *J*<sub>C-P</sub> = 7.6 Hz, Ar),

131.5 (d,  $J_{C-P} = 2.4$  Hz, Ar), 130.2 (s, Ar), 130.0 (s, Ar), 129.9 (d,  $J_{C-P} = 88.9$  Hz, Ar), 128.0 (s, Ar), 127.9 (s, Ar), 127.8 (s, Ar), 124.26 (s, Ar), 124.1 (s, Ar), 34.4 (d,  $J_{C-P} = 69.1$  Hz,  $C(CH_3)_3$ ), 24.7 (s,  $C(CH_3)_3$ ). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  33.0 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for  $C_{19}H_{21}$ NOP: 310.1355, found: 310.1354. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 80/20, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 6.879 min (major) and t<sub>R2</sub> = 22.645 min (minor), ee = 98%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +208.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(4-methylquinolin-2-yl)(phenyl)phosphine oxide (20): Performed according to the general procedure to afford 119 mg (74%) of **20** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.24–8.16 (m, 3 H, Ar), 8.06 (d, *J* = 4.0 Hz, 1 H, Ar), 7.97 (d, *J* = 8.4 Hz, 1 H, Ar), 7.71 (t, *J* = 7.4 Hz, 1 H, Ar), 7.57 (t, *J* = 7.6 Hz, 1 H, Ar), 7.42–7.33 (m, 3 H, Ar), 2.66 (s, 3 H,CH<sub>3</sub>), 1.23 (d, *J* = 15.1 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  157.2 (d, *J*<sub>C-P</sub> = 115.7 Hz, Ar), 147.5 (d, *J*<sub>C-P</sub> = 20.2 Hz, Ar), 144.4 (d, *J*<sub>C-P</sub> = 8.4 Hz, Ar), 132.9 (d, *J*<sub>C-P</sub> = 7.6 Hz, Ar), 131.4 (d, *J*<sub>C-P</sub> = 2.4 Hz, Ar), 130.9 (s, Ar), 130.2 (d, *J*<sub>C-P</sub> = 88.3 Hz, Ar), 129.5 (s, Ar), 128.1 (d, *J*<sub>C-P</sub> = 2.4 Hz, Ar), 127.7 (d, *J*<sub>C-P</sub> = 2.9 Hz, Ar), 124.8 (d, *J*<sub>C-P</sub> = 18.4 Hz, Ar), 124.0 (s, Ar), 34.3 (d, *J*<sub>C-P</sub> = 69.0 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.8 (s, *C*(CH<sub>3</sub>)<sub>3</sub>), 18.7 (s, CH<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  33.2 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>20</sub>H<sub>23</sub>NOP: 324.1512, found: 324.1510. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 5.285 min (major) and t<sub>R2</sub> = 9.705 min (minor), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +100.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(2-methylquinolin-4-yl)(phenyl)phosphine oxide (21): Performed according to the general procedure to afford 113 mg (70%) of 21 as yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.81 (d, *J* = 8.5 Hz, 1 H, Ar), 8.03 (d, *J* = 8.4 Hz, 1 H, Ar), 7.92–7.85 (m, 2 H, Ar), 7.66 (t, *J* = 12.1 Hz, 2 H, Ar), 7.55 (d, *J* = 6.6 Hz, 1 H, Ar), 7.51–7.42 (m, 3 H, Ar), 2.77 (s, 3 H, CH<sub>3</sub>), 1.40 (d, *J* = 15.1 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  156.8 (d, *J*<sub>C-P</sub> = 10.5 Hz, Ar), 148.6 (d, *J*<sub>C-P</sub> = 7.0 Hz, Ar), 137.2 (d, *J*<sub>C-P</sub> = 80.2 Hz, Ar), 132.1 (d, *J*<sub>C-P</sub> = 8.4 Hz, Ar), 131.9 (d, *J*<sub>C-P</sub> = 2.4 Hz, Ar), 131.0 (s, Ar), 129.7 (s, Ar), 129.3 (s, Ar), 128.5 (d, *J*<sub>C-P</sub> = 11.1 Hz, Ar), 127.8 (d, *J*<sub>C-P</sub> = 3.4 Hz, Ar), 126.8 (d, *J*<sub>C-P</sub> = 5.3 Hz, Ar), 126.5 (s, Ar), 126.3 (d, *J*<sub>C-P</sub> = 8.3 Hz, Ar), 34.8 (d, *J*<sub>C-P</sub> = 69.6 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 26.0 (s, C(CH<sub>3</sub>)<sub>3</sub>), 25.5 (s, CH<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  42.9 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>20</sub>H<sub>23</sub>NOP: 324.1512, found: 324.1510. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 8.792 min (minor) and t<sub>R2</sub> = 10.739min (major), ee = 98%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = -84.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(isoquinolin-1-yl)(phenyl)phosphine oxide (22): Performed according to the general procedure to afford 119 mg (77%) of 22 as yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.44 (d, *J* = 8.6 Hz, 1 H, Ar), 8.70 (d, *J* = 5.4 Hz, 1 H, Ar), 8.14–8.04 (m, 2 H, Ar), 7.81 (d, *J* = 8.1 Hz, 1 H, Ar), 7.74 (d, *J* = 5.2 Hz, 1 H, Ar), 7.65 (t, *J* = 7.5 Hz, 1 H,

Ar), 7.59–7.53 (m, 1 H, Ar), 7.50–7.40 (m, 3 H, Ar), 1.36 (d, J = 15.0 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$ 156.3 (d,  $J_{C-P} = 117.0 \text{ Hz}$ , Ar), 140.8 (s, Ar), 140.6 (s, Ar), 136.1 (d,  $J_{C-P} = 6.7 \text{ Hz}$ , Ar), 133.0 (d,  $J_{C-P} = 7.8 \text{ Hz}$ , Ar), 132.1 (d,  $J_{C-P} = 19.2 \text{ Hz}$ , Ar), 131.3 (d,  $J_{C-P} = 2.4 \text{ Hz}$ , Ar), 131.2 (d,  $J_{C-P} = 87.6 \text{ Hz}$ , Ar), 130.3 (s, Ar), 128.0 (s, Ar), 127.8 (s, Ar), 127.7 (s, Ar), 127.5 (s, Ar), 127.1 (s, Ar), 122.9 (d,  $J_{C-P} = 2.9 \text{ Hz}$ , Ar), 35.4 (d,  $J_{C-P} = 70.5 \text{ Hz}$ , C(CH<sub>3</sub>)<sub>3</sub>), 25.1 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  38.7 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>19</sub>H<sub>21</sub>NOP: 310.1355, found: 310.1353. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 95/05, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 26.065 min (minor) and t<sub>R2</sub> = 28.952 min (major), ee = 97%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = -28.0 (c = 1.0 in CHCl<sub>3</sub>).

$$\begin{bmatrix} \mathsf{N} & \mathsf{O} \\ \mathsf{N} & \mathsf{P} & \mathsf{O} \\ \mathsf{P} & \mathsf{P} \\ \mathsf{I} \\ \mathsf{f} \mathsf{B} \mathsf{u} \\ \end{bmatrix}$$

(*R*)-*tert*-butyl(phenyl)(pyrazin-2-yl)phosphine oxide (23): Performed according to the general procedure to afford 114 mg (88%) of 23 as yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.37 (s, 1 H, Ar), 8.78 (s, 1 H, Ar), 8.70 (t, *J* = 2.7 Hz, 1 H, Ar), 8.19–8.12 (m, 2 H, Ar), 7.55–7.45 (m, 3 H, Ar), 1.24 (d, *J* = 15.5 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  149.6 (d, *J*<sub>C-P</sub> = 17.4 Hz, Ar), 146.0 (s, Ar), 144.0 (d, *J*<sub>C-P</sub> = 13.3 Hz, Ar), 132.6 (d, *J*<sub>C-P</sub> = 7.7 Hz, Ar), 131.9 (s, Ar), 128.1 (d, *J*<sub>C-P</sub> = 11.1 Hz, Ar), 34.1 (d, *J*<sub>C-P</sub> = 69.8 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.4 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  32.5 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>OP: 261.1151, found: 261.1148. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 9.185 min (minor) and t<sub>R2</sub> = 16.112 min (major), ee = 97%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +173.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(3-methylpyrazin-2-yl)(phenyl)phosphine oxide (24): Performed according to the general procedure to afford 115 mg (84%) of 24 as yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.57–8.51 (m, 2 H, Ar), 7.85 (t, *J* = 8.6 Hz, 2 H, Ar), 7.50 (d, *J* = 6.9 Hz, 1 H, Ar), 7.43 (t, *J* = 7.3 Hz, 2 H, Ar), 2.72 (s, 3 H, *CH*<sub>3</sub>), 1.34–1.27 (m, 9 H, C(*CH*<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  159.9 (d, *J*<sub>C-P</sub> = 17.6 Hz, Ar), 150.8 (d, *J*<sub>C-P</sub> = 112.9 Hz, Ar), 144.6 (d, *J*<sub>C-P</sub> = 3.0 Hz, Ar), 140.2 (d, *J*<sub>C-P</sub> = 14.1 Hz, Ar), 132.5 (d, *J*<sub>C-P</sub> = 8.1 Hz, Ar), 131.7 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 130.2 (d, *J*<sub>C-P</sub> = 88.8 Hz, Ar), 128.0 (d, *J*<sub>C-P</sub> = 11.0 Hz, Ar), 35.0 (d, *J*<sub>C-P</sub> = 71.1 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.8 (s, C(*C*H<sub>3</sub>)<sub>3</sub>), 22.8 (s, *C*H<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  33.1 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>15</sub>H<sub>20</sub>N<sub>2</sub>OP: 275.1308, found: 275.1304. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 90/10, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 7.519min (major) and t<sub>R2</sub> = 8.092 min (minor), ee = 97%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +21.0 (c = 1.0 in CHCl<sub>3</sub>).

(*R*)-*tert*-butyl(6-(dimethylamino)pyrazin-2-yl)(phenyl)phosphine oxide (25): Performed according to the general procedure to afford 121 mg (80%) of 25 as yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.54 (s, 1 H, Ar), 8.19–8.13 (m, 3 H, Ar), 7.53–7.43 (m, 3 H, Ar), 3.22 (s, 6 H, N(CH<sub>3</sub>)<sub>2</sub>), 1.25 (d, *J* = 15.1 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  153.2 (d, *J*<sub>C-P</sub> = 15.0 Hz, Ar), 147.6 (d, *J*<sub>C-P</sub> = 114.2 Hz, Ar), 136.2 (d, *J*<sub>C-P</sub> = 18.4 Hz, Ar), 132.4 (d, *J*<sub>C-P</sub> = 7.6 Hz, Ar), 131.9 (d, *J*<sub>C-P</sub> = 2.6 Hz, Ar), 131.4 (s, Ar), 129.82 (d, *J*<sub>C-P</sub> = 89.8 Hz, Ar), 127.7 (d, *J*<sub>C-P</sub> = 10.9 Hz, Ar), 37.8 (s, N(CH<sub>3</sub>)<sub>2</sub>), 33.8 (d, *J*<sub>C-P</sub> = 69.6 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.5 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  32.5 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>23</sub>N<sub>3</sub>OP: 304.1573, found: 304.1571. HPLC analysis of the product: Daicel Chiralpak AD-H column;

*n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm,  $t_{R1}$  = 11.279 min (major) and  $t_{R2}$  = 13.519 min (minor), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +229.0 (c = 1.0 in CHCl<sub>3</sub>).

(*R*)-*tert*-butyl(6-chloropyrazin-2-yl)(phenyl)phosphine oxide (26): Performed according to the general procedure to afford 73 mg (50%) of **26** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.26 (s, 1 H, Ar), 8.71 (d, *J* = 2.5 Hz, 1 H, Ar), 8.15–8.09 (m, 2 H, Ar), 7.56–7.48 (m, 3 H, Ar), 1.25 (d, *J* = 15.7 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  152.0 (d, *J*<sub>C-P</sub> = 105.0 Hz, Ar), 148.8 (d, *J*<sub>C-P</sub> = 13.5 Hz, Ar), 147.2 (d, *J*<sub>C-P</sub> = 16.1 Hz, Ar), 146.3 (d, *J*<sub>C-P</sub> = 2.6 Hz, Ar), 132.5 (d, *J*<sub>C-P</sub> = 7.9 Hz, Ar), 132.1 (d, *J*<sub>C-P</sub> = 2.8 Hz, Ar), 128.4 (d, *J*<sub>C-P</sub> = 91.7 Hz, Ar), 128.3 (d, *J*<sub>C-P</sub> = 11.3 Hz, Ar), 34.3 (d, *J*<sub>C-P</sub> = 70.0 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.4 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  32.2 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>14</sub>H<sub>17</sub>ClN<sub>2</sub>OP: 295.0762, found: 295.0760. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 98/02, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 38.425 min (minor) and t<sub>R2</sub> = 42.452 min (major), ee = 97%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +193.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(phenyl)(quinoxalin-2-yl)phosphine oxide (27): Performed according to the general procedure to afford 144 mg (93%) of 27 as yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.60 (s, 1 H, Ar), 8.29–8.21 (m, 3 H, Ar), 8.10–8.15 (m, 1 H, Ar), 7.90–7.84 (m, 2 H, Ar), 7.55–7.46 (m, 3 H, Ar), 1.32 (d, *J* = 15.5 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  152.6 (d, *J*<sub>C-P</sub> = 109.1 Hz, Ar), 147.3 (d, *J*<sub>C-P</sub> = 18.8 Hz, Ar), 142.5 (d, *J*<sub>C-P</sub> = 2.3 Hz, Ar), 141.7 (d, *J*<sub>C-P</sub> = 15.6 Hz, Ar), 132.7 (d, *J*<sub>C-P</sub> = 7.8 Hz, Ar), 131.9 (d, *J*<sub>C-P</sub> = 2.8 Hz, Ar), 131.8 (s, Ar), 130.68 (s, Ar), 130.1 (d, *J*<sub>C-P</sub> = 0.8 Hz, Ar), 129.7 (d, *J*<sub>C-P</sub> = 1.6 Hz, Ar), 129.6 (s, Ar), 128.7 (s, Ar), 128.2 (s, Ar), 128.0 (s, Ar), 34.6 (d, *J*<sub>C-P</sub> = 69.3 Hz, C(CH<sub>3</sub>)<sub>3</sub>), 24.5 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  33.2 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>OP: 311.1308, found: 311.1307. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 13.772 min (major) and t<sub>R2</sub> = 21.719 min (minor), ee = 98%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +153.0 (c = 1.0 in CHCl<sub>3</sub>).

(*R*)-*tert*-butyl(phenyl)(pyrimidin-2-yl)phosphine oxide (28): Performed according to the general procedure to afford 107 mg (83%) of **28** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.94 (d, *J* = 4.7 Hz, 2 H, Ar), 8.10 (t, *J* = 8.8 Hz, 2 H, Ar), 7.52 (d, *J* = 7.3 Hz, 1 H, Ar), 7.48–7.39 (m, 3 H, Ar), 1.30 (d, *J* = 15.3 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  156.6 (d, *J*<sub>C-P</sub> = 12.6 Hz, Ar), 132.9 (d, *J*<sub>C-P</sub> = 8.0 Hz, Ar), 131.73 (s, Ar), 127.9 (d, *J*<sub>C-P</sub> = 11.2 Hz, Ar), 121.9 (s, Ar), 34.1 (d, *J*<sub>C-P</sub> = 69.5 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.8 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  35.0 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>OP: 261.1151, found: 261.1149. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 11.839 min (minor) and t<sub>R2</sub> = 12.679 min (major), ee = 98%. [ $\alpha$ ]<sub>p</sub><sup>20</sup> = +173.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(5-methylpyrimidin-2-yl)(phenyl)phosphine oxide (29): Performed according to the general procedure to afford 122 mg (89%) of **29** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.75 (s, 2 H, Ar), 8.09 (t, *J* = 8.6 Hz, 2 H, Ar), 7.53–7.41 (m, 3 H, Ar), 2.38 (s, 3 H, *CH*<sub>3</sub>), 1.29 (d, *J* = 15.2 Hz, 9 H, C(*CH*<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  156.8 (d, *J*<sub>C-P</sub> = 13.1 Hz, Ar), 132.9 (d, *J*<sub>C-P</sub> = 8.1 Hz, Ar), 131.8 (d, *J*<sub>C-P</sub> = 2.4 Hz, Ar), 131.6 (d, *J*<sub>C-P</sub> = 2.2 Hz, Ar), 127.8 (d, *J*<sub>C-P</sub> = 11.1 Hz, Ar), 34.0 (d, *J*<sub>C-P</sub> = 69.9 Hz, *C*(*CH*<sub>3</sub>)<sub>3</sub>), 24.8 (s, C(*CH*<sub>3</sub>)<sub>3</sub>), 15.9 (s, *CH*<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  34.8 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>15</sub>H<sub>20</sub>N<sub>2</sub>OP: 275.1308, found: 275.1304. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 12.525 min (major) and t<sub>R2</sub> = 22.972 min (minor), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +141.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(4,6-dimethylpyrimidin-2-yl)(phenyl)phosphine oxide (30): Performed according to the general procedure to afford 119 mg (83%) of **30** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.12–8.05 (m, 2 H, Ar), 7.52–7.47 (m, 1 H, Ar), 7.46–7.40 (m, 2 H, Ar), 7.09 (d, *J* = 2.6 Hz, 1 H, Ar), 2.56 (s, 6 H, CH<sub>3</sub>), 1.30 (d, *J* = 15.1 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  166.5 (d, *J*<sub>C-P</sub> = 13.4 Hz, Ar), 166.3 (d, *J*<sub>C-P</sub> = 144.0 Hz, Ar), 133.0 (d, *J*<sub>C-P</sub> = 8.0 Hz, Ar), 131.5 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 129.4 (d, *J*<sub>C-P</sub> = 90.0 Hz, Ar), 127.7 (d, *J*<sub>C-P</sub> = 11.1 Hz, Ar), 121.0 (d, *J*<sub>C-P</sub> = 2.5 Hz, Ar), 34.0 (d, *J*<sub>C-P</sub> = 69.5 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.9 (s, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.0 (s, *C*H<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  34.3 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>22</sub>N<sub>2</sub>OP: 289.1464, found: 289.1462. HPLC analysis of the product: Daicel Chiralpak AS-H column; *n*-hexane/*i*-PrOH = 90/10, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 7.879 min (major) and t<sub>R2</sub> = 11.565 min (minor), ee = 99%. [ $\alpha$ ]<sub>p</sub><sup>20</sup> = +89.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-[2,2'-bipyridin]-6-yl(*tert*-butyl)(phenyl)phosphine oxide (31): Performed according to the general procedure to afford 147 mg (87%) of **31** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.73 (d, *J* = 4.3 Hz, 1 H, Ar), 8.58 (d, *J* = 8.1 Hz, 1 H, Ar), 8.45 (d, *J* = 7.9 Hz, 1 H, Ar), 8.30–8.21 (m, 3 H, Ar), 7.99–7.90 (m, 2 H, Ar), 7.52–7.43 (m, 3 H, Ar), 7.41–7.36 (m, 1 H, Ar), 1.31 (d, *J* = 15.1 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  156.2 (d, *J*<sub>C-P</sub> = 62.5 Hz, Ar), 155.6 (s, Ar), 155.6 (d, *J*<sub>C-P</sub> = 37.8 Hz, Ar), 149.4 (s, Ar), 137.2 (t, *J*<sub>C-P</sub> = 4.3 Hz, Ar), 132.7 (d, *J*<sub>C-P</sub> = 7.6 Hz, Ar), 131.5 (d, *J*<sub>C-P</sub> = 2.6 Hz, Ar), 130.1 (d, *J*<sub>C-P</sub> = 89.6 Hz, Ar), 129.3 (s, Ar), 129.2 (s, Ar), 127.9 (d, *J*<sub>C-P</sub> = 10.9 Hz, Ar), 124.2 (s, Ar), 122.6 (d, *J*<sub>C-P</sub> = 2.9 Hz, Ar), 120.9 (s, Ar), 33.9 (d, *J*<sub>C-P</sub> = 69.6 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.8 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  33.0 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>OP: 337.1464, found: 337.1462. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 80/20, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 6.365 min (major) and t<sub>R2</sub> = 6.739 min (minor), ee = 99%. [ $\alpha$ ]<sub>D<sup>20</sup></sub> = +117.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-[2,2'-bipyridin]-4-yl(*tert*-butyl)(phenyl)phosphine oxide (32): Performed according to the general procedure to afford 151 mg (90%) of **32** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.97 (d, *J* = 10.1 Hz, 1 H, Ar), 8.83 (t, *J* = 4.1 Hz, 1 H, Ar), 8.70 (d, *J* = 4.1 Hz, 1 H, Ar), 8.42 (d, *J* = 8.0 Hz, 1 H, Ar), 8.05–7.98 (m, 2 H, Ar), 7.96–7.90 (m, 1 H, Ar), 7.86–7.79 (m, 1 H, Ar), 7.58–7.49 (m, 3 H, Ar), 7.35–7.30 (m, 1 H, Ar), 1.31 (d, *J* = 15.3 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  155.9 (d, *J*<sub>C-P</sub> = 8.9 Hz, Ar), 155.3 (d, *J*<sub>C-P</sub> = 1.4 Hz, Ar), 149.4 (s, Ar), 149.32 (s, Ar), 141.8 (d, *J*<sub>C-P</sub> = 82.8 Hz, Ar), 137.0 (s, Ar), 132.2 (d, *J*<sub>C-P</sub> = 8.2 Hz, Ar), 132.0 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 129.8 (d, *J*<sub>C-P</sub> = 91.5 Hz, Ar), 128.6 (d, *J*<sub>C-P</sub> = 11.1 Hz, Ar), 126.5 (d, *J*<sub>C-P</sub> = 6.0 Hz, Ar), 124.1 (s, Ar), 122.9 (d, *J*<sub>C-P</sub> = 8.0 Hz, Ar), 121.2 (s, Ar), 34.1 (d, *J*<sub>C-P</sub> = 70.5 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 25.1 (s, *C*(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  37.3 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>OP: 337.1464, found: 337.1461. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 9.899 min (minor) and t<sub>R2</sub> = 11.185 min (major), ee = 99%. [ $\alpha$ ]<sub>D<sup>20</sup></sub> = +114.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(1,10-phenanthrolin-2-yl)(phenyl)phosphine oxide (33): Performed according to the general procedure to afford 160 mg (89%) of **33** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.28–9.20 (m, 1 H, Ar), 8.63–8.56 (m, 2 H, Ar), 8.54–8.49 (m, 1 H, Ar), 8.36–8.30 (m, 1 H, Ar), 8.25–8.20 (m, 1 H, Ar), 7.84–7.75 (m, 2 H, Ar), 7.68–7.62 (m, 1 H, Ar), 7.48 (d, *J* = 2.2 Hz, 3 H, Ar), 1.37 (d, *J* = 15.2 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  157.1 (d, *J*<sub>C-P</sub> = 118.2 Hz, Ar), 150.9 (s, Ar), 146.7 (s, Ar), 146.0 (d, *J*<sub>C-P</sub> = 18.5 Hz, Ar), 135.8 (s, Ar), 135.6 (d, *J*<sub>C-P</sub> = 8.3 Hz, Ar) 133.4 (d, *J*<sub>C-P</sub> = 7.6 Hz, Ar), 131.3 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 130.0 (d, *J*<sub>C-P</sub> = 89.4 Hz, Ar), 129.0 (s, Ar), 128.8 (d, *J*<sub>C-P</sub> = 2.8 Hz, Ar), 128.3 (s, Ar), 127.9 (d, *J*<sub>C-P</sub> = 10.9 Hz, Ar), 126.5 (d, *J*<sub>C-P</sub> = 18.6 Hz, Ar), 126.3 (s, Ar), 123.3 (s, Ar), 34.1 (d, *J*<sub>C-P</sub> = 69.1 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.8 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  33.6 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>22</sub>N<sub>2</sub>OP: 361.1464, found: 361.1463. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 13.272 min (minor) and t<sub>R2</sub> = 14.252 min (major), ee = 98%. [\alpha]<sub>D</sub><sup>20</sup> = +216.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-*tert*-butyl(9-chloro-1,10-phenanthrolin-2-yl)(phenyl)phosphine oxide (34): Performed according to the general procedure to afford 108 mg (55%) of **34** as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.68–8.58 (m, 2 H, Ar), 8.54–8.48 (m, 1 H, Ar), 8.39–8.32 (m, 1 H, Ar), 8.19 (d, *J* = 8.4 Hz, 1 H, Ar), 7.82 (s, 2 H, Ar), 7.66 (d, *J* = 8.4 Hz, 1 H, Ar), 7.55–7.49 (m, 3 H, Ar), 1.34 (d, *J* = 15.2 Hz, 9 H, C(*CH*<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 157.6 (d, *J*<sub>C-P</sub> = 117.4 Hz, Ar), 151.7 (s, Ar), 146.4 (s, Ar), 144.7 (d, *J*<sub>C-P</sub> = 18.6 Hz, Ar), 138.5 (s, Ar), 135.6 (d, *J*<sub>C-P</sub> = 8.2 Hz, Ar), 133.7 (d, *J*<sub>C-P</sub> =

7.5 Hz, Ar), 131.5 (d,  $J_{C-P} = 2.7$  Hz, Ar), 129.7 (d,  $J_{C-P} = 90.0$  Hz, Ar), 129.0 (d,  $J_{C-P} = 2.8$  Hz, Ar), 128.0 (s, Ar), 127.6 (s, Ar), 126.7 (s, Ar), 124.5 (s, Ar), 34.1 (d,  $J_{C-P} = 69.0$  Hz,  $C(CH_3)_3$ ), 24.7 (s,  $C(CH_3)_3$ ). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  33.8 (s). HRMS (ESI): m/z: [M+H]+ calculated for C22H21CIN2OP: 395.1075, found: 395.1077. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 13.172 min (minor) and t<sub>R2</sub> = 25.485 min (major), ee = 97%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +206.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-[2,2':6',2"-terpyridin]-4'-yl(*tert*-butyl)(phenyl)phosphine oxide (35): Performed according to the general procedure to afford 183 mg (89%) of 35 as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.06 (d, *J* = 10.3 Hz, 2 H, Ar), 8.74–8.67 (m, 2 H, Ar), 8.60 (d, *J* = 7.9 Hz, 2 H, Ar), 8.10–8.03 (m, 2 H, Ar), 7.88–7.81 (m, 2 H, Ar), 7.57–7.49 (m, 3 H, Ar), 7.36–7.31 (m, 2 H, Ar), 1.36 (d, *J* = 15.3 Hz, 9 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  155.6 (d, *J*<sub>C-P</sub> = 9.3 Hz, Ar), 155.4 (s, Ar), 149.4 (s, Ar), 142.9 (d, *J*<sub>C-P</sub> = 83.3 Hz, Ar), 136.8 (s, Ar), 132.3 (d, *J*<sub>C-P</sub> = 8.2 Hz, Ar), 131.9 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 130.0 (d, *J*<sub>C-P</sub> = 91.2 Hz, Ar), 128.5 (d, *J*<sub>C-P</sub> = 11.1 Hz, Ar), 124.1 (s, Ar), 123.4 (d, *J*<sub>C-P</sub> = 7.8 Hz, Ar), 121.3 (s, Ar), 34.2 (d, *J*<sub>C-P</sub> = 70.4 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 25.2 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  37.2 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>25</sub>N<sub>3</sub>OP: 414.1730, found: 414.1727. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 9.919 min (minor) and t<sub>R2</sub> = 11.079 min (major), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +84.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-cyclohexyl(phenyl)(quinoxalin-2-yl)phosphine oxide (39): Performed according to the general procedure to afford 106 mg (60%) of 39 as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  9.50 (s, 1 H, Ar), 8.27 – 8.20 (m, 1 H, Ar), 8.19 – 8.12 (m, 1 H, Ar), 8.11 – 8.01 (m, 2 H, Ar), 7.90 – 7.83 (m, 2 H, Ar), 7.50 (t, *J* = 7.4 Hz, 3 H, Ar), 2.77 – 2.65 (m, 1 H, Cy), 1.83 – 1.64 (m, 7 H, Cy), 1.28 (d, *J* = 8.1 Hz, 3 H, Cy). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  151.5 (d, *J*<sub>C-P</sub> = 112.9 Hz, Ar), 145.5 (d, *J*<sub>C-P</sub> = 19.5 Hz, Ar), 141.6 (d, *J*<sub>C-P</sub> = 2.2 Hz, Ar), 141.2 (d, *J*<sub>C-P</sub> = 16.2 Hz, Ar), 130.9 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 130.6 (s, Ar), 130.5 (s, Ar), 130.4 (s, Ar), 129.7 (s, Ar), 129.6 (s, Ar), 129.0 (s, Ar), 128.8 (s, Ar), 128.7 (d, *J*<sub>C-P</sub> = 1.6 Hz, Ar), 127.5 (s, Ar), 127.4 (s, Ar), 36.2 (d, *J*<sub>C-P</sub> = 2.3 Hz, Cy). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  31.8 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>OP: 337.1464, found: 337.1462. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 12.539 min (major) and t<sub>R2</sub> = 13.965 min (minor), ee = 98%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +73.0 (c = 1.0 in CHCl<sub>3</sub>).



(*R*)-cyclohexyl(phenyl)(pyrimidin-2-yl)phosphine oxide (40): Performed according to the general procedure to afford 76 mg (50%) of 40 as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.90 (s, 2 H, Ar), 8.11 – 7.90 (m, 2 H, Ar), 7.54

-7.43 (m, 3 H, Ar), 7.37 (s, 1 H, Ar), 2.64 (d, *J* = 14.5 Hz, 1 H, Cy), 1.70 (t, *J* = 39.3 Hz, 7 H, Cy), 1.27 (s, 3 H, Cy). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.8 (s, Ar), 167.3 (s, Ar), 157.0 (d, *J*<sub>C-P</sub> = 12.8 Hz, Ar), 131.8 (d, *J*<sub>C-P</sub> = 2.7 Hz, Ar), 131.7 (s, Ar), 131.6 (s, Ar), 130.4 (s, Ar), 129.4 (s, Ar), 128.5 (s, Ar), 128.4 (s, Ar), 121.8 (s, Ar), 36.9 (d, *J*<sub>C-P</sub> = 73.5 Hz, Cy), 26.3 (d, *J*<sub>C-P</sub> = 23.8 Hz, Cy), 26.3 (d, *J*<sub>C-P</sub> = 4.1 Hz, Cy), 25.8 (d, *J*<sub>C-P</sub> = 1.0 Hz, Cy), 25.8 (d, *J*<sub>C-P</sub> = 1.0 Hz, Cy), 24.7 (d, *J*<sub>C-P</sub> = 3.4 Hz, Cy), 24.1 (d, *J*<sub>C-P</sub> = 2.3 Hz, Cy). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 30.8 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>20</sub>N<sub>2</sub>OP: 287.1308, found: 287.1306. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 13.992 min (major) and t<sub>R2</sub> = 17.232 min (minor), ee = 97%. [α]<sub>D</sub><sup>20</sup> = -4.0 (c = 1.0 in CHCl<sub>3</sub>).



(*1R,1'R*)-(1,10-phenanthroline-2,9-diyl)bis(*tert*-butyl(phenyl)phosphine oxide (41): Performed according to the general procedure to afford 221 mg (82%) of 41 as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.79–8.70 (m, 2 H, Ar), 8.45 (t, *J* = 8.9 Hz, 6 H, Ar), 7.94 (s, 2 H, Ar), 7.48 (d, *J* = 7.0 Hz, 2 H, Ar), 7.42 (d, *J* = 5.4 Hz, 4 H, Ar), 1.46 (d, *J* = 15.3 Hz, 18 H, C(CH<sub>3</sub>)<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  158.0 (d, *J*<sub>C-P</sub> = 115.1 Hz, Ar), 146.3 (d, *J*<sub>C-P</sub> = 18.3 Hz, Ar), 136.3 (d, *J*<sub>C-P</sub> = 8.3 Hz, Ar), 132.8 (d, *J*<sub>C-P</sub> = 7.8 Hz, Ar), 131.6 (d, *J*<sub>C-P</sub> = 2.6 Hz, Ar), 130.2 (s, Ar), 129.7 (d, *J*<sub>C-P</sub> = 2.5 Hz, Ar), 129.3 (s, Ar), 128.4 (s, Ar), 128.0 (s, Ar), 127.9 (s, Ar), 127.8 (s, Ar), 127.6 (s, Ar), 34.1 (d, *J*<sub>C-P</sub> = 69.2 Hz, *C*(CH<sub>3</sub>)<sub>3</sub>), 24.9 (s, C(CH<sub>3</sub>)<sub>3</sub>). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  33.5 (s). HRMS (ESI): m/z: [M+H]<sup>+</sup> calculated for C<sub>32</sub>H<sub>35</sub>N<sub>2</sub>O<sub>2</sub>P<sub>2</sub>: 541.2168, found: 541.2171. HPLC analysis of the product: Daicel Chiralpak AD-H column; *n*-hexane/*i*-PrOH = 85/15, flow rate = 1 mL/min, UV = 254 nm, t<sub>R1</sub> = 15.545 min (major ) and t<sub>R2</sub> = 18.132 min (minor), ee = 99%. [ $\alpha$ ]<sub>D</sub><sup>20</sup> = +130.0 (c = 1.0 in CHCl<sub>3</sub>).

#### 3. X-ray structural determination

The X-ray date was collected on a Rigaku Saturn CCDC diffractometer using graphite-monochromated Mo K $\alpha$  radiation ( $\lambda = 0.71073$  Å). The structure was solved by direct methods (SHELXS-97)<sup>2</sup> and refined by full-matrix least squares on  $F^2$ . All non-hydrogen atoms were refined anisotropically and hydrogen atoms by a riding model (SHELXL-97).<sup>3</sup> The crystal data and structural refinements details are listed in Table S1. CCDC 2121510 (**23**) contains the supplementary crystallographic data for this paper. This data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <u>www.ccdc.cam.ac.uk/data\_request/cif</u>.

	23
formula	C <sub>14</sub> H <sub>17</sub> N <sub>2</sub> OP
fw	260.26
<i>Т</i> (К)	296
space group	P 21 21 21
crystal system	orthorhombic
<i>a</i> (Å)	7.2488(9)
b (Å)	10.7508(14)
<i>c</i> (Å)	17.638(2)
lpha (deg.)	90
<i>θ</i> (deg.)	90
γ (deg.)	90
V (Å3)	1374.5(3)
Ζ	4
dcalcd. (mg/cm3)	1.258
F(000)	552.0
GOF	1.094
R1 ( $l > 2\sigma(l)$ )	0.0339
wR2 (all data)	0.0887

Table S1. Crystal Data and Summary of X-ray Data Collection for compound 23

#### 4. Computational Methods

All the calculations were carried out via density functional theory (DFT) calculation using Gaussian 16<sup>4</sup> with the  $\omega$ B97XD <sup>5</sup> functional. Geometric structures of all species in this work were optimized in gas phase. In addition, free energy corrections were considered at a concentration of 1 M and a temperature of 298.15 K. Frequency calculation were performed to determine all the stationary points (no imaginary frequency) and transition state structures (only one imaginary frequency). The 6-31+G(d) <sup>6</sup> basis set was used for all atoms. In addition, the intrinsic reaction coordinate (IRC) calculation <sup>7</sup> were applied to confirm the connection of each transition state to its corresponding appropriate intermediates, reactants, or products. Base on the gas phase optimized geometries, solvent effects were computed by using the SMD <sup>8</sup> model at the same level of theory while 6-311++G(d,p) basis set for all atoms. Dimethylsulfoxide ( $\epsilon$  = 46.826) was used as the solvent, and Bondi atomic radii <sup>9</sup> was used for the SMD calculation. All 3D molecular structures were drawn by using the CYLview (Version) program <sup>10</sup>. The Mulliken charge distribution were calculated by Gaussian 16 with the level of  $\omega$ B97XD/6-31+G(d). The spin-orbit crossing (SOC) values were calculated by ORCA package.<sup>11</sup>



Figure S2. The spin-orbit coupling (SOC) values of <sup>3</sup>[INT-C] and <sup>3</sup>[4]. The data were obtained by ORCA package.

corrected relative electronic energies ( $\Delta E_{sol}$ ) calculated for species involved in Figure 1 and 54.			
ΔGgas	ΔEgas	ΔEsol	
0	0	0	
-0.1	0.9	1.7	
-10.8	-12.7	-13.2	
-10.2	2.5	-7.8	
41.2	56.2	45.1	
47.7	62.1	48.8	
27.1	42.2	26.5	
47.5	60.6	42.2	
	ΔGgas           0           -0.1           -10.8           -10.2           41.2           47.7           27.1           47.5	ΔGgas         ΔEgas           0         0           -0.1         0.9           -10.8         -12.7           -10.2         2.5           41.2         56.2           47.7         62.1           27.1         42.2           47.5         60.6	

**Table S2**. The gas phase relative free energies ( $\Delta G_{gas}$ ), gas phase relative electronic energies ( $\Delta E_{gas}$ ) and solvation corrected relative electronic energies ( $\Delta E_{sol}$ ) calculated for species involved in Figure 1 and S4.

[INT-C]*	43.7	30.8	21.8
<sup>3</sup> [4]	69.0	113.1	72.2
4	-9.5	30.0	-9.6













INT-B











<sup>3</sup>[INT-D]











4

**Table S3**. Absolute Calculation Energies and imaginary frequencies.

Species	E(gas-wB97XD) <sup>1</sup>	G( <sub>corr-wB97XD</sub> ) <sup>2</sup>	H( <sub>corr-ωB97XD</sub> ) <sup>3</sup>	E( <sub>solv-ωB97XD</sub> ) <sup>4</sup>	IF <sup>5</sup>
INT-A	-2858.779859	0.415255	0.528451	-2859.204566	-
TS1	-2858.778420	0.413667	0.525253	-2859.201785	-625.80
INT-B	-2858.800083	0.418200	0.530840	-2859.225637	-
INT-C	-2782.379064	0.392087	0.502670	-2782.776262	-
<sup>3</sup> [INT-C]	-2782.293526	0.388416	0.500064	-2782.692023	-
<sup>3</sup> [TS <sub>2</sub> ]	-2782.284071	0.389322	0.499403	-2782.686064	-251.86
<sup>3</sup> [INT-D]	-2782.315831	0.388290	0.502282	-2782.721631	-
<sup>3</sup> [TS <sub>3</sub> ]	-2782.286418	0.391374	0.500490	-2782.696614	-451.09
[INT-C]*	-2782.295863	0.394726	0.502652	-2782.673437	-
<sup>3</sup> [4]	-1053.430809	0.249699	0.315773	-1053.638198	-
4	-1053.563191	0.256958	0.320239	-1053.768480	-

<sup>1</sup>The electronic energy calculated by  $\omega$ B97XD in gas phase. <sup>2</sup>The thermal correction to Gibbs free energy calculated by  $\omega$ B97XD in gas phase. <sup>3</sup>The thermal correction to enthalpy calculated by  $\omega$ B97XD in gas phase. <sup>4</sup>The electronic energy calculated by  $\omega$ B97XD in dimethylsulfoxide solvent. <sup>5</sup>The  $\omega$ B97XD calculated imaginary frequencies for the transition states.

# Cartesian coordinates for the complexes calculated in this study: [gas phase results optimized at the level of $\omega$ B97XD/6-31+G(d)]

INT-A			
Р	-0.92873500	0.35301500	1.15641700
Н	0.40977300	0.03456900	1.57249700
0	-1.21230400	-0.06608900	-0.27565300
С	-1.13974300	2.15054200	1.37820900
С	-1.94012900	2.85865100	0.47802500
С	-0.47588700	2.84204000	2.39658800
С	-2.08458400	4.23925500	0.59919100

Н	-2.43508500	2.31912700	-0.32524000
С	-0.62051000	4.22237100	2.52032400
н	0.17296500	2.30303900	3.08283700
С	-1.42539500	4.92212300	1.62110300
н	-2.70867700	4.78334700	-0.10459700
н	-0.10043900	4.75277700	3.31347500
н	-1.53570800	5.99910000	1.71521800
С	-2.04241600	-0.49199100	2.36530900
С	-3.50376900	-0.14105200	2.06184000
н	-4.16835300	-0.70732600	2.72755200
Н	-3.70284300	0.92613300	2.21673000
н	-3.76168100	-0.39353700	1.02736500
С	-1.67081300	-0.08821500	3.79777600
н	-2.26563400	-0.67469900	4.50977900
н	-0.61217800	-0.28120700	4.01137300
н	-1.87586200	0.97118800	3.98887800
С	-1.80375500	-1.99811400	2.16151800
Н	-0.75363700	-2.26710900	2.32966300
н	-2.41973400	-2.56943300	2.86838800
н	-2.07368000	-2.30335100	1.14565100
Na	1.16172200	-0.76863400	-0.88515500
S	0.29204500	0.69387100	-3.92919100
С	1.78909700	1.71195800	-3.96054900
н	1.55451100	2.68491500	-4.40401600
н	2.15036700	1.82102800	-2.93204000
Н	2.52158400	1.18958000	-4.58048000
С	-0.66435500	1.72254900	-2.78863400
н	-0.07488500	1.90785500	-1.88577400
н	-0.93129300	2.65308000	-3.30107800
н	-1.55910900	1.15678100	-2.52146000
0	0.66783000	-0.57296600	-3.17424300
S	2.39075600	2.07270200	0.57665000
С	2.76631400	3.82538700	0.29614700
н	3.32791700	4.22316300	1.14748700
н	3.33656000	3.93944000	-0.63066100
н	1.80855000	4.34619300	0.21409400
С	4.07383600	1.43464500	0.58019700
н	4.56369100	1.69301900	-0.36365100
н	4.61735600	1.84930400	1.43518200
н	3.92325800	0.35509900	0.69982100
0	1.77745800	1.62588000	-0.75171400
0	2.06404200	-0.68385500	1.13772000
н	2.29724600	-1.43173700	1.69833700
С	0.01060600	-4.08567200	-0.15551500
			519

С	-1.05826000	-4.95871000	0.04114400
С	-2.22353600	-4.70482100	-0.67207100
С	-2.26998000	-3.61094400	-1.53362400
С	-1.14030200	-2.80943900	-1.64666600
Ν	-0.01033100	-3.04545600	-0.96559600
Н	-3.08551500	-5.35491400	-0.55194200
Н	-0.97180100	-5.79464000	0.72543900
Н	-3.16282700	-3.37737700	-2.10358000
Н	-1.11173600	-1.93921700	-2.29436500
Cl	1.49680300	-4.36845600	0.71960800
TS1			
Р	0.50869700	-1.17968200	-2.29110300
Н	1.95092900	-1.63178200	-1.97017400
0	0.18939600	-1.50729400	-3.75436800
С	0.33073500	0.62490900	-2.01605900
С	-0.36949200	1.39154400	-2.95118800
С	0.95252900	1.26779500	-0.94001700
С	-0.45957200	2.77574000	-2.80840400
Н	-0.83074600	0.88980600	-3.79794100
С	0.86104300	2.64991900	-0.79136200
Н	1.53387200	0.68610400	-0.22792800
С	0.15402400	3.40684300	-1.72685600
Н	-1.00856600	3.36229700	-3.54058400
Н	1.34729300	3.13851400	0.04904900
Н	0.08542300	4.48563000	-1.61407000
С	-0.71984700	-1.98550700	-1.15056600
С	-2.14203500	-1.54693700	-1.51746200
Н	-2.87365900	-2.09356700	-0.90683200
Н	-2.29007600	-0.47498900	-1.34048900
Н	-2.35378500	-1.75304600	-2.57254300
С	-0.40442500	-1.63835200	0.30928800
Н	-1.06144400	-2.21215100	0.97621700
Н	0.63225800	-1.88641400	0.57018800
Н	-0.56776900	-0.57523500	0.51858500
С	-0.56203300	-3.49816300	-1.37558500
Н	0.45469400	-3.83725400	-1.14019200
Н	-1.25962300	-4.04782300	-0.72936600
Н	-0.77686100	-3.76357300	-2.41568300
Na	2.48245400	-2.20049300	-4.43871300
S	1.56366800	-0.85671600	-7.48840800
С	3.05546000	0.15699700	-7.64729300
Н	2.79012500	1.12127000	-8.09237000
Н	3.49151600	0.28690200	-6.65101500

Н	3.74203700	-0.37854900	-8.30717300
С	0.68604100	0.20031500	-6.31213100
Н	1.34692300	0.42921500	-5.47091200
Н	0.35757100	1.10531800	-6.83424900
н	-0.16814500	-0.37075300	-5.94174000
0	1.99068100	-2.10347400	-6.72520000
S	3.69025700	0.62557200	-3.05066800
С	3.97763300	2.39632000	-3.29934200
Н	4.40338600	2.82979500	-2.38909800
н	4.64409400	2.54914200	-4.15345100
Н	3.00198900	2.84973100	-3.49335000
С	5.39631900	0.10128300	-2.81254500
н	5.98543700	0.36233400	-3.69670800
Н	5.80070400	0.57496700	-1.91258100
Н	5.32048600	-0.98047100	-2.67095200
0	3.29456500	0.11740700	-4.43851100
0	3.31043900	-2.10508100	-2.30908900
Н	3.50819200	-2.91068300	-1.81691600
С	1.42401700	-5.53754400	-3.59599400
С	0.38048000	-6.43917100	-3.39593700
С	-0.78461800	-6.22962000	-4.12357500
С	-0.85458700	-5.14934200	-5.00035600
С	0.25128900	-4.31573500	-5.11411700
Ν	1.38193900	-4.50952300	-4.41988500
Н	-1.62854800	-6.90255800	-4.00191800
Н	0.48479000	-7.26200200	-2.69846700
Н	-1.74850100	-4.94955700	-5.58125400
н	0.25976900	-3.45518100	-5.77501500
Cl	2.91154100	-5.76679300	-2.70279300

INT-B

Р	-0.62063200	0.20054600	1.43763200
н	1.51499600	-0.62995400	1.49689700
0	-0.84278800	-0.03205600	-0.09759900
С	-0.82531500	2.03803100	1.67119000
С	-1.43961200	2.81042000	0.67918800
С	-0.30027900	2.69527300	2.78991600
С	-1.54888200	4.19490900	0.80823700
н	-1.83375800	2.30090100	-0.19644800
С	-0.40575300	4.07940400	2.92810000
н	0.20453700	2.11400900	3.56048200
С	-1.03189400	4.83479500	1.93574000
н	-2.04099600	4.77670100	0.03192400
н	0.00227000	4.57024900	3.80866100

Н	-1.11469000	5.91363000	2.03990700	
С	-2.19127400	-0.42418000	2.29287800	
С	-3.44926500	0.16089800	1.64522600	
н	-4.35024700	-0.32892300	2.04303600	
н	-3.53968000	1.23578900	1.84030400	
н	-3.42656600	0.01064400	0.55932700	
С	-2.15145000	-0.09776800	3.78850000	
н	-3.00161800	-0.56776400	4.30299800	
н	-1.23097800	-0.47079500	4.25700700	
н	-2.21151400	0.98198300	3.96868800	
С	-2.17964700	-1.94684900	2.09360600	
н	-1.28656300	-2.40451800	2.53993300	
н	-3.06285000	-2.40363300	2.56310300	
н	-2.19299000	-2.19558900	1.02701600	
Na	1.09280100	-0.67684100	-1.08638300	
S	0.00911600	0.61478800	-4.01923000	
С	1.47481200	1.62827400	-4.33722600	
н	1.16076000	2.60539400	-4.71766200	
н	2.03455800	1.73098700	-3.40176400	
н	2.07173700	1.11150300	-5.09220800	
С	-0.71200000	1.64135600	-2.71781100	
н	0.06354300	1.90893400	-1.99464000	
н	-1.16617300	2.52561900	-3.17667000	
н	-1.46021200	1.03225800	-2.20323300	
0	0.52477300	-0.64807700	-3.33657100	
S	2.39548600	1.98724900	0.30072700	
С	2.21375000	3.78119100	0.23543500	
н	2.51872100	4.21018800	1.19413900	
н	2.81268000	4.18144400	-0.58806200	
н	1.15150700	3.98567100	0.07907400	
С	4.18197500	1.90223300	0.54371900	
н	4.68847200	2.39366500	-0.29202400	
н	4.44347100	2.37314500	1.49600900	
н	4.43178200	0.83970500	0.57694700	
0	2.16324200	1.50330400	-1.13128400	
0	2.32349600	-0.94230600	1.01323100	
н	2.36787900	-1.89072500	1.19325700	
С	0.10390900	-4.06990500	0.02464800	
С	-0.97072500	-4.92493900	0.25227500	
С	-2.11153400	-4.71812600	-0.51340800	
С	-2.12435500	-3.68583200	-1.44788700	
С	-0.99068200	-2.89389300	-1.57910400	
Ν	0.12025100	-3.08641000	-0.85059800	
н	-2.98112600	-5.35340300	-0.37369200	
			~~~	

	Н	-0.91008100	-5.70849100	0.99818700
	Н	-2.99796000	-3.48797900	-2.05925100
	Н	-0.94342600	-2.07321800	-2.28877800
	Cl	1.57017700	-4.31633800	0.96341600
I	INT-C			
	Р	-0.72865300	-1.12752100	0.37990600
	С	-1.33145200	-1.39396800	2.12508700
	С	-1.90201200	-0.34950600	2.86129200
	С	-1.14628100	-2.62567700	2.76342200
	С	-2.29493300	-0.53156600	4.18621800
	Н	-2.02635100	0.61652200	2.37560600
	С	-1.54415800	-2.81998000	4.08624100
	Н	-0.67675000	-3.44285300	2.21741300
	С	-2.11973300	-1.77103100	4.80317800
	Н	-2.73976800	0.29227500	4.74008900
	Н	-1.39654100	-3.78693400	4.56144000
	Н	-2.42385800	-1.91647900	5.83662200
	С	-2.30601800	-1.64317500	-0.55957000
	С	-3.52400100	-0.81160500	-0.15178900
	н	-4.38313000	-1.03986700	-0.80039900
	Н	-3.82146700	-1.01343800	0.88347800
	Н	-3.30649600	0.25934700	-0.23926500
	С	-2.58335800	-3.13409800	-0.34281400
	Н	-3.40338900	-3.46861500	-0.99466100
	Н	-1.70040600	-3.74358100	-0.57738900
	н	-2.87548100	-3.34521600	0.69222300
	С	-1.99372100	-1.39643500	-2.04180500
	Н	-1.12557400	-1.98437300	-2.36645600
	Н	-2.84997400	-1.68003300	-2.67162000
	Н	-1.77287300	-0.33870300	-2.22632100
	0	-0.69117200	0.45071600	0.24193700
	Na	1.02685100	1.52814300	-0.64195100
	S	2.78328100	1.69984500	2.36063700
	С	4.32159400	0.74856500	2.29179100
	н	4.49240000	0.25893200	3.25511400
	н	4.24709500	0.01238400	1.48693600
	Н	5.13251200	1.44907900	2.08096200
	С	1.65493100	0.31874700	2.63744800
	Н	1.79949500	-0.44836200	1.86996100
	Н	1.81686500	-0.09006300	3.63950600
	Н	0.63849000	0.70832600	2.55230600
	0	2.53940600	2.18190200	0.93784500
	С	2.12499100	-1.24526900	-2.33082700

С	1.92897300	-2.30298200	-3.21540300
С	1.14863100	-2.05434800	-4.33773800
С	0.60149400	-0.78636300	-4.52114200
С	0.85067100	0.18519300	-3.56102700
Ν	1.60933600	-0.03963300	-2.47821700
Н	0.96535000	-2.84731200	-5.05673500
Н	2.37000800	-3.27384600	-3.02360300
Н	-0.02061700	-0.55843000	-5.37974200
Н	0.42616600	1.18384400	-3.62454100
Cl	3.13991400	-1.49549300	-0.93057600
S	-1.81053000	2.76392900	-1.91150900
С	-2.40941700	4.35535600	-2.53456500
Н	-3.48841800	4.42962900	-2.36913400
Н	-1.87917800	5.16304400	-2.02208400
Н	-2.19483600	4.39308700	-3.60486600
С	-2.18536900	3.01398300	-0.16643200
Н	-1.69270200	3.92841600	0.17872000
Н	-3.27048500	3.07812600	-0.03767600
Н	-1.78630100	2.11956800	0.33504800
0	-0.29148500	2.84763900	-2.04507700

<sup>3</sup>[INT-C]

С	-2.29975700	1.82088900	0.03506100
С	-0.88377400	2.41340300	1.74520100
С	-1.94542100	2.56050100	2.60932500
С	-3.26243800	2.29016600	2.18452200
С	-3.42433300	1.95014500	0.79728800
Н	0.12612500	2.67921500	2.04872900
Н	-1.75092200	2.90540500	3.62285300
Н	-4.11931600	2.41888500	2.83569800
Н	-4.40492200	1.80778700	0.35652100
Ν	-1.00991900	1.97791400	0.41674200
Cl	-2.48861700	1.42707300	-1.69460000
Na	0.79097000	1.50161000	-1.01244300
Ρ	0.39621700	-0.40995700	1.55105600
0	1.37837400	-0.60382100	0.39547800
С	-0.99894100	-1.57118400	1.45650400
С	-0.80497300	-2.87435900	0.97877900
С	-2.28115300	-1.14709900	1.81586900
С	-1.88398600	-3.74476800	0.86311800
Н	0.19377700	-3.20279000	0.70232800
С	-3.36055500	-2.02110400	1.69309000
Н	-2.44660700	-0.13455000	2.17552100

С	-3.16568200	-3.31543200	1.21656700
Н	-1.72867100	-4.75907400	0.50365200
Н	-4.35600000	-1.67982300	1.96215200
н	-4.00995000	-3.99271700	1.12017500
С	1.22679100	-0.65046000	3.20943700
C	1.83994200	-2.05803700	3.26713300
Н	2.36588600	-2.18629900	4.22287000
Н	1.07121200	-2.83629700	3.20359000
Н	2.56199000	-2.21146000	2.45766700
С	0.18602700	-0.46559900	4.32021300
Н	0.68175900	-0.53445900	5.29709000
Н	-0.30464300	0.51213700	4.25267100
Н	-0.58953400	-1.23833200	4.28207000
С	2.32743000	0.41333600	3.32212200
Н	1.90851700	1.42584900	3.30957500
Н	2.86641900	0.28430300	4.26945000
Н	3.05057200	0.32983200	2.50374600
S	3.94423100	1.63084900	-2.26523200
С	3.33413200	1.30010700	-3.93842800
Н	4.06474500	0.68655600	-4.47491100
Н	2.36606900	0.79323600	-3.86842700
Н	3.22805400	2.26609200	-4.43748500
С	3.87927000	-0.07374000	-1.65990100
Н	2.86941000	-0.46305300	-1.81473800
Н	4.62855600	-0.67136900	-2.18885500
Н	4.10032800	-0.04963100	-0.59092000
0	2.82345400	2.37304300	-1.55320700
S	-0.24973500	-1.25705800	-2.17371600
C	0.79434800	-2.73022200	-2.12278600
Н	0.18117100	-3.60933800	-1.90429200
Н	1.31162500	-2.83968400	-3.08067500
Н	1.50896700	-2.56241300	-1.31342500
C	-1.27566100	-1.72327200	-3.58547400
Н	-0.64020500	-1.92974500	-4.45132700
Н	-1.87807400	-2.59672200	-3.31839500
Н	-1.93201300	-0.87566100	-3.79265700
0	0.66882000	-0.15040900	-2.69589900
3[TS	2]		
C	-1.83969100	2.38835400	0.35059900
C	-0.10098500	3.14037700	1.67306200
C	-0.88254000	3.16877200	2.80849000
C	-2.24005400	2.70661500	2.70279700
C	-2.68283600	2.26131700	1.47890200
			323

н	0.94442700	3.44942100	1.72576300
н	-0.47518400	3.52646800	3.74909000
н	-2.91167800	2.74873800	3.55674500
н	-3.69409400	1.88440800	1.34511800
Ν	-0.51394200	2.75515000	0.44484700
Cl	-2.15853400	1.16355900	-1.02312800
Na	1.01832400	1.74386700	-1.02632200
Р	0.37396800	-0.17897900	1.63185700
0	1.43152500	-0.21859600	0.53566000
С	-0.82671200	-1.53698100	1.45284000
С	-0.41297600	-2.77923800	0.95687800
С	-2.17022800	-1.33087800	1.77473100
С	-1.33469000	-3.80907200	0.79506900
н	0.63257600	-2.93508100	0.70279900
С	-3.09164700	-2.36339700	1.60981900
Н	-2.49594300	-0.35583100	2.12977700
С	-2.67624700	-3.60011700	1.12054000
Н	-1.00891700	-4.77656700	0.42138700
Н	-4.13698700	-2.19604100	1.85217100
Н	-3.39704400	-4.40271100	0.99074700
С	1.11772500	-0.30602400	3.34123000
С	1.83291400	-1.66186600	3.46269200
Н	2.31084100	-1.72641000	4.44915900
Н	1.13425100	-2.50112100	3.37577700
Н	2.61230100	-1.77275600	2.70058300
С	-0.00022300	-0.18544900	4.38422400
Н	0.44104400	-0.21299900	5.38869200
Н	-0.54594500	0.75818100	4.27492500
Н	-0.71540400	-1.01252100	4.31183400
С	2.12691700	0.83887400	3.49858100
Н	1.62867900	1.81201900	3.45818800
Н	2.62461900	0.74897600	4.47254400
Н	2.89444600	0.80796900	2.71790400
S	4.28213700	1.67615800	-2.04577500
С	3.80857200	1.19406400	-3.72648100
Н	4.56357100	0.51436500	-4.13413100
Н	2.82183100	0.72012500	-3.69302600
Н	3.77595200	2.10782100	-4.32437200
С	4.12544000	0.03905200	-1.28901400
Н	3.11476600	-0.33452800	-1.47364300
н	4.88748500	-0.62649900	-1.70702600
Н	4.27763700	0.16015500	-0.21460000
0	3.12490600	2.50004700	-1.50561700
S	0.07846500	-1.15253300	-2.15314300

С	1.06683500	-2.65600700	-2.34139500
Н	0.43769100	-3.53206900	-2.15784400
Н	1.50391300	-2.68821800	-3.34377800
Н	1.85578200	-2.60642500	-1.58708600
С	-1.05929500	-1.42755300	-3.52854900
Н	-0.49505000	-1.55840800	-4.45632700
Н	-1.67922200	-2.30284900	-3.31267100
Н	-1.69104400	-0.53876600	-3.59207100
0	1.00015100	-0.02384500	-2.61505000
<sup>3</sup> [INT-D]			
С	-3.16776200	1.28758700	-0.73922700
С	-1.63194100	2.49063100	0.41445900
С	-2.58394800	2.83998200	1.36223600
С	-3.89290300	2.37009400	1.21566100
С	-4.21864500	1.56805300	0.12410200
Н	-0.59851300	2.81725700	0.46855000
Н	-2.30635000	3.46351000	2.20584200
Н	-4.65157700	2.62414200	1.95176600
Н	-5.21831600	1.17954400	-0.03362000
Ν	-1.94977400	1.69843800	-0.62990800
Cl	-1.04949100	-1.93223400	-1.42163000
Na	0.15123000	0.43992800	-1.29279800
Р	0.63762300	-0.09845100	2.33950000
0	0.78465400	0.51378800	0.96184000
С	-1.09173000	-0.37987000	2.81874100
С	-2.01066700	-0.82875600	1.86175400
С	-1.50072800	-0.15275200	4.13791400
С	-3.33042500	-1.05983600	2.23988000
Н	-1.70257900	-1.02286600	0.83400300
С	-2.82525300	-0.37903900	4.50427300
Н	-0.78873700	0.20725400	4.87768800
С	-3.73897700	-0.83422300	3.55352300
Н	-4.03609400	-1.41787900	1.49608900
Н	-3.14318300	-0.20070000	5.52776000
Н	-4.77188200	-1.01455300	3.83961300
С	1.57987400	-1.70596800	2.49803400
С	0.81478200	-2.80713100	1.74538400
Н	1.42784400	-3.71895100	1.74070200
Н	-0.13443500	-3.04464800	2.23638900
Н	0.59235100	-2.53592500	0.70716400
С	1.71994000	-2.06571100	3.98228200
н	2.25238200	-3.02066100	4.07485700
н	2.28693600	-1.30837200	4.53676000

Н	0.74165300	-2.18711400	4.46186300
С	2.95447400	-1.47700900	1.85538800
Н	3.51848400	-0.68554000	2.36415500
Н	3.53986500	-2.40320200	1.91869600
Н	2.85135700	-1.20057400	0.80121600
S	2.51818400	2.98303500	-1.57930500
С	3.24866900	2.27524000	-3.07881700
Н	4.33044800	2.44260000	-3.07060800
н	3.01019600	1.20654600	-3.10676100
н	2.80107700	2.79442600	-3.92950100
С	3.34148400	1.89112800	-0.39183700
н	3.13862700	0.85256800	-0.67000000
н	4.41420900	2.11109900	-0.39466900
Н	2.91133600	2.09975700	0.58946300
0	1.05415500	2.58004600	-1.60209900
S	2.24728200	-2.15112200	-2.06844900
С	3.96364000	-2.54120900	-2.50875300
Н	4.07131800	-3.62119100	-2.64828600
Н	4.24015300	-2.00308400	-3.42017300
Н	4.59449000	-2.21389800	-1.67872300
С	1.48282000	-2.67313300	-3.61704400
Н	1.92742900	-2.10980800	-4.44275700
Н	1.63391000	-3.74942200	-3.74421500
Н	0.41623700	-2.45933600	-3.50760800
0	2.21160000	-0.62171000	-2.07040000
<sup>3</sup> [TS <sub>3</sub> ]			
C	-0.66540500	-0.07682100	1.00504000
C	0.47660300	1.86947300	0.69761200
C	0.09549800	2.30978600	1.96685600
C	-0.85540200	1.56544200	2.69851600
С	-1.29469300	0.35112900	2.21014500
Н	1.11946800	2.44946300	0.04113800
Н	0.44651600	3.26978100	2.33085000
Н	-1.25657900	1.95855400	3.62945200
Н	-2.00430100	-0.27896300	2.73574000
Ν	-0.01800000	0.73406300	0.19354600
Cl	-0.79698000	-1.98704900	-2.95299800
Na	1.05601100	-0.52881900	-1.76614100
Р	0.86354200	-1.70560500	1.49565700
0	1.71454600	-1.75129900	0.24762800
С	-0.37213700	-3.02960000	1.54480600
С	-0.89720000	-3.39682400	0.29687900
С	-0.89849000	-3.60298400	2.71134100

С	-1.91861000	-4.34042600	0.22184800
н	-0.54010600	-2.94047900	-0.62566600
С	-1.91097400	-4.55368800	2.62685600
н	-0.52043800	-3.33034800	3.69065800
С	-2.42310000	-4.92308500	1.38177500
н	-2.31990000	-4.59782900	-0.75380700
н	-2.30238200	-5.00428500	3.53475200
н	-3.22097600	-5.65821900	1.32135900
С	1.94024100	-1.64320800	3.02742300
С	2.52446200	-3.04278200	3.28687300
Н	3.25763400	-2.98051200	4.10230200
Н	1.75919800	-3.76823700	3.57832700
Н	3.03749800	-3.42756100	2.39906100
С	1.19175400	-1.11513200	4.25932900
н	1.86990900	-1.13320200	5.12213600
н	0.86500800	-0.08182700	4.11110100
н	0.31253800	-1.70950300	4.52283000
С	3.08062000	-0.66965600	2.68466600
н	2.69876700	0.32671200	2.43154500
н	3.74011500	-0.57018400	3.55619300
Н	3.66930600	-1.03542000	1.83928500
S	3.90792900	1.39616600	-2.02107300
С	4.14894100	0.62922200	-3.64250200
Н	5.22215400	0.53615700	-3.83672600
Н	3.65975800	-0.35034100	-3.65453400
Н	3.69810700	1.29847900	-4.37902400
С	4.56242000	0.04602600	-1.00867400
Н	3.98934100	-0.86349800	-1.22055100
Н	5.62557300	-0.08934400	-1.23211800
Н	4.43692200	0.34598800	0.03404500
0	2.40494900	1.40596800	-1.77568700
S	2.19074000	-3.42993800	-2.42252700
С	3.65160000	-4.45669900	-2.10961600
Н	3.36006300	-5.51079400	-2.07093300
Н	4.39589500	-4.28681700	-2.89326600
н	4.05210600	-4.15043800	-1.14034800
С	1.80516300	-4.04334200	-4.07447700
Н	2.67037500	-3.89517300	-4.72735000
н	1.53150000	-5.10107400	-4.01116500
н	0.94460600	-3.45702600	-4.40770900
0	2.77019300	-2.02986500	-2.63549700
[INT-C]*			

[]

Ľ	
-	

-2.01810800 2.10295500 0.03203900 S29

С	-0.53444000	2.99474200	1.52843400
С	-1.39602000	2.76018300	2.56922100
С	-2.61954700	2.07254900	2.35568100
С	-2.95802500	1.82814500	0.98244700
н	0.39621200	3.53566100	1.68224500
н	-1.13194700	3.12099600	3.56126800
н	-3.35595400	1.95324100	3.14167500
н	-3.93984600	1.46893200	0.69217800
N	-0.76504600	2.58351200	0.21527400
Cl	-2.45187500	1.85529500	-1.68604300
Na	0.98263300	1.66287300	-1.01100400
Р	0.07790800	-0.38014200	1.55317400
0	1.08232900	-0.34498800	0.40678400
С	-1.02669200	-1.83033000	1.42630200
С	-0.52698900	-3.08455200	1.05944400
С	-2.39087200	-1.67699700	1.68647200
С	-1.38368900	-4.17794300	0.95665300
н	0.53399600	-3.20480200	0.85736000
С	-3.24734600	-2.77193300	1.57934600
н	-2.77670600	-0.69942100	1.96165500
С	-2.74548300	-4.01998300	1.21544700
н	-0.98991700	-5.15238600	0.68022900
н	-4.30799100	-2.64780900	1.77662900
н	-3.41461700	-4.87228700	1.13566300
С	0.91075800	-0.44778500	3.21957300
С	1.74622500	-1.73358000	3.32448200
Н	2.28195700	-1.73381700	4.28258200
н	1.11965000	-2.63149100	3.29533400
Н	2.48887000	-1.79580200	2.52128200
С	-0.16668500	-0.41434100	4.31088700
Н	0.31671100	-0.39659400	5.29573600
Н	-0.79990600	0.47352700	4.22168900
н	-0.81060900	-1.30042800	4.27197000
С	1.82600900	0.78035000	3.32305200
Н	1.25147500	1.70852800	3.26691400
н	2.35407500	0.75697600	4.28464700
Н	2.57447100	0.79023800	2.52344200
S	4.14194100	1.21596800	-2.19671600
С	3.52419600	0.95236900	-3.87894800
н	4.14627100	0.20336700	-4.37906600
н	2.47903500	0.62965400	-3.82689700
н	3.60616500	1.90722600	-4.40325600
С	3.76059600	-0.43379100	-1.55591000
н	2.69983700	-0.63627900	-1.72651700

Н	4.39793100	-1.17094800	-2.05457500
н	3.96513200	-0.42146900	-0.48340900
0	3.15416200	2.16119900	-1.53204900
S	-0.47223700	-0.94476300	-2.23419000
С	0.31990200	-2.56858500	-2.24811200
Н	-0.42130700	-3.34231700	-2.02851000
Н	0.79261600	-2.73501500	-3.22071900
Н	1.07183900	-2.54680100	-1.45725600
С	-1.53833900	-1.18144700	-3.67254200
Н	-0.92891000	-1.44689000	-4.54094700
Н	-2.27350500	-1.96094800	-3.45138100
Н	-2.05010400	-0.23308400	-3.84543200
0	0.61919700	0.01966000	-2.69766400

<sup>3</sup>[4]

С	-3.75707800	-0.65556400	-0.01282400
С	-3.40624600	0.14130700	1.06496700
С	-3.39961300	1.53700200	0.89392800
С	-3.95398100	2.08904000	-0.31667600
С	-4.24961800	1.25745100	-1.35326400
Ν	-3.70479700	-0.01903500	-1.24966100
Н	-3.19529700	2.18753800	1.73699000
н	-3.28076800	-0.32039700	2.04024200
Н	-4.18516900	3.14731500	-0.38796400
Н	-4.71047000	1.55510700	-2.28869200
Р	-4.28599000	-2.37541300	0.22476400
0	-4.29510700	-2.74268700	1.67911700
С	-3.14247300	-3.41433600	-0.74019100
С	-2.84201600	-4.67691100	-0.21769300
С	-2.58304600	-3.01845100	-1.95959300
С	-2.00543000	-5.54237100	-0.91877500
Н	-3.25613800	-4.96596600	0.74436600
С	-1.74687500	-3.88646900	-2.65761400
Н	-2.78384000	-2.02772900	-2.35902500
С	-1.46097800	-5.14941700	-2.14029000
Н	-1.77408800	-6.52088400	-0.50772800
Н	-1.31128600	-3.57245400	-3.60189900
Н	-0.80595600	-5.82337300	-2.68545700
С	-5.95773300	-2.51460300	-0.57043700
С	-6.45574600	-3.94679600	-0.31475900
Н	-7.47093400	-4.05450200	-0.71703200
Н	-5.81979200	-4.69024000	-0.80940100
Н	-6.48302600	-4.17222200	0.75588000
С	-5.91848500	-2.23912400	-2.07901900

Н	-6.93822300	-2.29798300	-2.48026200
Н	-5.53408200	-1.23814100	-2.31042300
Н	-5.30560400	-2.97199900	-2.61369800
С	-6.87980100	-1.50415500	0.13148500
Н	-6.56876800	-0.47030300	-0.06116100
Н	-7.90378900	-1.62383900	-0.24415500
Н	-6.89057600	-1.66164600	1.21481700
4			
С	-3.98941500	-0.58728300	-0.01814200
С	-3.71660800	0.14431200	1.13747100
С	-3.40315900	1.49459100	1.00654900
С	-3.37705200	2.05530200	-0.26598500
С	-3.66631500	1.23911900	-1.35855000
Ν	-3.96876800	-0.05558300	-1.24844700
н	-3.18352000	2.09737000	1.88309000
Н	-3.75426800	-0.35285300	2.10168400
Н	-3.13799800	3.10331500	-0.41688700
н	-3.65611500	1.64155400	-2.36899200
Р	-4.41923600	-2.36348700	0.18490500
0	-4.39133600	-2.74118400	1.63997300
С	-3.21181500	-3.31345200	-0.79294300
С	-2.70221500	-4.47178200	-0.19716900
С	-2.79629900	-2.95532100	-2.08108100
С	-1.79409000	-5.27205400	-0.88764100
Н	-3.01425800	-4.72893700	0.81143600
С	-1.88579900	-3.75638000	-2.76545900
Н	-3.17494800	-2.04666400	-2.53929700
С	-1.38740000	-4.91617900	-2.17208500
Н	-1.40099200	-6.17013800	-0.41964000
Н	-1.56292300	-3.47307600	-3.76335900
н	-0.67768200	-5.53898900	-2.70978400
С	-6.09630700	-2.61491000	-0.57290100
С	-6.51241600	-4.05318500	-0.21911700
Н	-7.52068100	-4.24139100	-0.60920400
Н	-5.83713700	-4.78992600	-0.67043400
Н	-6.52222900	-4.21264700	0.86320700
С	-6.11770900	-2.42765700	-2.09563700
Н	-7.14948700	-2.54769200	-2.45065500
Н	-5.76568800	-1.43504400	-2.39158200
Н	-5.50350100	-3.17892100	-2.60307300
С	-7.05229400	-1.61419300	0.09788900
Н	-6.81813700	-0.58140700	-0.18477000
н	-8.08012200	-1.82341400	-0.22409700

## 5. References

- (a) F. A. Kortmann, M.-C. Chang, E. Otten, E. P. A. Couzijn, M. Lutzc and A. J. Minnaard, *Chem. Sci.*, 2014, 5, 1322; (b) G. Tran, D. G. Pardo, T. Tsuchiya, S. Hillebrand, J.-P. Vors and J. Cossy, *Org. Lett.*, 2013, 15, 21, 5550; (c) Y. Niu, P.-B. Bai, Q.-X. Lou and S.-D. Yang, *ChemCatChem*, 2020, 12, 3644. (d) B. Varga, P. Szemesi, P. Nagy, R. Herbay, T. Holczbauer, E. Fogassy, G. Keglevich and P. Bagi, *J. Org. Chem.*, 2021, 86, 14493.
- 2 G. M. Sheldrick, SHELXS-90/96, Program for Structure Solution, Acta Crystallogr. Sect A, 1990, 46, 467.
- 3 G. M. Sheldrick, SHELXL 97, Program for Crystal structure Refinement, University of Goettingen: Geottingen, Germany, 1997.
- M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2016.
- (a) S.-Y. Song, Y. Li, Z. Ke, S. Xu, Iridium-Catalyzed Enantioselective C–H Borylation of Diarylphosphinates. *ACS Catal.* 2021, 11, 13445–13451. (b) A. Maiti, F. Zhang, I. Krummenacher, M. Bhattacharyya, S. Mehta, M. Moos, C. Lambert, B. Engels, A. Mondal, H. Braunschweig, P. Ravat, A. Jana, Anionic Boron- and Carbon-Based Hetero-Diradicaloids Spanned by a p-Phenylene Bridge. *J. Am. Chem. Soc.* 2021, 143, 3687.
- 6 P. C. Hariharan, J. A. Pople, The Influence of Polarization Functions on Molecular Orbital Hydrogenation Energies. *Theoret. Chim. Acta.* **1973**, 28, 213.
- 7 K. Fukui, The Path of Chemical Reactions the IRC Approach. Acc. Chem. Res. 1981, 14, 363.
- A. V. Marenich, C. J. Cramer, D. G. Truhlar, Universal Solvation Model Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic Surface Tensions. J. Phys. Chem. B. 2009, 113, 6378.
- 9 A. Bondi, van der Waals Volumes and Radii. J. Phys. Chem. 1964, 68, 441.

- 10 C. Y. Legault, CYLview, 1.0b; Universitéde Sherbrooke: Quebec, Canada, 2009 (http://www.cylview.org).
- 11 (a) F. Neese, The ORCA program system, Wiley Interdiscip. Rev.: Comput. Mol. Sci. 2012, 2, 73. (b) F. Neese, Software update: the ORCA program system, version 4.0, Wiley Interdiscip. Rev.: Comput. Mol. Sci. 2017, 8, e1327.

6. <sup>1</sup>H, <sup>13</sup>C, <sup>19</sup>F and <sup>31</sup>P NMR spectra for all products.



Figure S3. <sup>1</sup>H NMR spectrum of 4 in CDCl<sub>3</sub>



130 110 90 80 70 60 50 40 30 20 10 0 -10 -30 -50 -70 -90 -110 -130 -150 -170 -190 -210 -230 fl (ppm)

Figure S5. <sup>31</sup>P NMR spectrum of 4 in CDCl<sub>3</sub>



Figure S7. <sup>13</sup>C NMR spectrum of 5 in CDCl<sub>3</sub>


Figure S9. <sup>1</sup>H NMR spectrum of 6 in CDCl<sub>3</sub>







Figure S11.  $^{\rm 31}P$  NMR spectrum of 6 in CDCl\_3



Figure S12. <sup>1</sup>H NMR spectrum of 7 in  $CDCI_3$ 



Figure S13. <sup>13</sup>C NMR spectrum of 7 in CDCl<sub>3</sub>



Figure S15. <sup>1</sup>H NMR spectrum of 8 in CDCl<sub>3</sub>









Figure S17. <sup>31</sup>P NMR spectrum of 8 in CDCl<sub>3</sub>



Figure S19. <sup>13</sup>C NMR spectrum of 9 in CDCl<sub>3</sub>



Figure S20.  $^{\rm 31}P$  NMR spectrum of 9 in CDCl3



Figure S21. <sup>1</sup>H NMR spectrum of **12** in CDCl<sub>3</sub>









Figure S23. <sup>31</sup>P NMR spectrum of 12 in CDCl<sub>3</sub>







Figure S25. <sup>13</sup>C NMR spectrum of 13 in CDCl<sub>3</sub>



Figure S27.  $^{19}\mathsf{F}$  NMR spectrum of 13 in  $\mathsf{CDCI}_3$ 



Figure S28. <sup>1</sup>H NMR spectrum of 14 in CDCl<sub>3</sub>



Figure S29. <sup>13</sup>C NMR spectrum of **14** in CDCl<sub>3</sub>



Figure S30. <sup>31</sup>P NMR spectrum of 14 in CDCl<sub>3</sub>







Figure S32.  $^{\rm 13}C$  NMR spectrum of 15 in CDCl\_3



Figure S33. <sup>31</sup>P NMR spectrum of 15 in CDCl<sub>3</sub>



Figure S34. <sup>19</sup>F NMR spectrum of **15** in CDCl<sub>3</sub>



Figure S35.  $^1\!\text{H}$  NMR spectrum of 16 in  $\text{CDCl}_3$ 



Figure S36.  $^{\rm 13}C$  NMR spectrum of 16 in  ${\rm CDCI}_{\rm 3}$ 

-37.27





Figure S37. <sup>31</sup>P NMR spectrum of **16** in CDCl<sub>3</sub>









Figure S41. <sup>1</sup>H NMR spectrum of 18 in CDCl<sub>3</sub>





Figure S43. <sup>31</sup>P NMR spectrum of 18 in CDCl<sub>3</sub>



















130 110 90 80 70 60 50 40 30 20 10 0 -10 -30 -50 -70 -90 -110 -130 -150 -170 -190 -210 -230 f1 (ppm)

Figure S49. <sup>31</sup>P NMR spectrum of 20 in CDCl<sub>3</sub>



Figure S50. <sup>1</sup>H NMR spectrum of 21 in CDCl<sub>3</sub>



Figure S51. <sup>13</sup>C NMR spectrum of 21 in CDCl<sub>3</sub>



Figure S52.  $^{\rm 31}P$  NMR spectrum of 21 in CDCl\_3



Figure S53. <sup>1</sup>H NMR spectrum of 22 in CDCl<sub>3</sub>









Figure S55.  $^{\rm 31}P$  NMR spectrum of 22 in CDCl\_3





Figure S57. <sup>13</sup>C NMR spectrum of 23 in CDCl<sub>3</sub>



Figure S58.  $^{\rm 31}P$  NMR spectrum of 23 in CDCl\_3



Figure S59.  $^1\text{H}$  NMR spectrum of 24 in CDCl\_3

*t*Bu



Figure S60.  $^{\rm 13}C$  NMR spectrum of 24 in CDCl\_3



Figure S61. <sup>31</sup>P NMR spectrum of 24 in CDCl<sub>3</sub>



Figure S62.  $^1\!H$  NMR spectrum of 25 in CDCl\_3



Figure S63. <sup>13</sup>C NMR spectrum of 25 in CDCl<sub>3</sub>











Figure S66.  $^{\rm 13}{\rm C}$  NMR spectrum of 26 in  ${\rm CDCI}_{\rm 3}$ 



Figure S67. <sup>31</sup>P NMR spectrum of 26 in CDCl<sub>3</sub>



Figure S68.  $^1\text{H}$  NMR spectrum of 27 in CDCl\_3



Figure S69. <sup>13</sup>C NMR spectrum of 27 in CDCl<sub>3</sub>











Figure S72. <sup>13</sup>C NMR spectrum of 28 in CDCl<sub>3</sub>



130 110 90 80 70 60 50 40 30 20 10 0 -10 -30 -50 -70 -90 -110 -130 -150 -170 -190 -210 -230 f1 (ppm)

Figure S73. <sup>31</sup>P NMR spectrum of 28 in CDCl<sub>3</sub>



Figure S74. <sup>1</sup>H NMR spectrum of 29 in CDCl<sub>3</sub>



Figure S75. <sup>13</sup>C NMR spectrum of 29 in CDCl<sub>3</sub>



Figure S76.  $^{\rm 31}P$  NMR spectrum of 29 in CDCl\_3



Figure S77. <sup>1</sup>H NMR spectrum of (*R*)-30 in CDCl<sub>3</sub>









130 110 90 80 70 60 50 40 30 20 10 0 -10 -30 -50 -70 -90 -110 -130 -150 -170 -190 -210 -230 f1 (ppm)

Figure S79. <sup>31</sup>P NMR spectrum of 30 in CDCl<sub>3</sub>












Figure S83. <sup>1</sup>H NMR spectrum of 32 in CDCl<sub>3</sub>



130 110 90 80 70 60 50 40 30 20 10 0 -10 -30 -50 -70 -90 -110 -130 -150 -170 -190 -210 -230 f1 (ppm)

Figure S85. <sup>31</sup>P NMR spectrum of 32 in CDCl<sub>3</sub>



Figure S87. <sup>13</sup>C NMR spectrum of 33 in CDCl<sub>3</sub>







Figure S89. <sup>1</sup>H NMR spectrum of 34 in CDCl<sub>3</sub>



Figure S90.  $^{\rm 13}C$  NMR spectrum of 34 in  $\rm CDCI_3$ 



130 110 90 80 70 60 50 40 30 20 10 0 -10 -30 -50 -70 -90 -110 -130 -150 -170 -190 -210 -230 f1 (ppm)

Figure S91.  $^{31}\text{P}$  NMR spectrum of 34 in CDCl\_3





















0.02010.02010.02

Figure S97. <sup>31</sup>P NMR spectrum of **39** in CDCl<sub>3</sub>









Figure S100. <sup>31</sup>P NMR spectrum of 40 in CDCl<sub>3</sub>



Figure S101. <sup>1</sup>H NMR spectrum of 41 in CDCl<sub>3</sub>

### -138.52 -157.37 -157.37 -157.57 -157.57 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -131.54 -13



Figure S102.  $^{\rm 13}C$  NMR spectrum of 41 in CDCl\_3



Figure S103. <sup>31</sup>P NMR spectrum of 41 in CDCl<sub>3</sub>

# 7. HPLC spectra for all products.

Chiral HPLC chromatographic analysis of **4** 

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 90/10, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =12.392 min, t (major) = 13.512 min, ee = 98%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =5.965 min, t (minor) = 6.979 min, ee = 97%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =11.099 min, t (minor) = 22.752 min, ee = 99%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 98/2, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =42.386 min, t (major) = 45.219 min, ee = 99%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =4.832 min, t (minor) = 5.279 min, ee = 99%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =5.652 min, t (minor) = 6.192 min, ee = 99%.



Chiral HPLC chromatographic analysis of  ${\bf 12}$ 

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =9.312 min, t (major) = 19.099 min, ee = 98%.



## Chiral HPLC chromatographic analysis of ${\bf 13}$

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =7.739 min, t (minor) = 8.505 min, ee = 99%.



## Chiral HPLC chromatographic analysis of ${\bf 14}$

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =5.925 min, t (minor) = 6.412 min, ee = 99%.



## Chiral HPLC chromatographic analysis of ${\bf 15}$

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 90/10, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =7.925 min, t (minor) = 22.659 min, ee = 97%.



## Chiral HPLC chromatographic analysis of ${\bf 16}$

Condition: Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 95/5, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =11.859 min, t (major) = 13.179 min, ee = 98%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =17.125 min, t (major) = 17.919 min, ee = 99%.



## Chiral HPLC chromatographic analysis of ${\bf 18}$

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =5.639 min, t (minor) = 7.379 min, ee = 99%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 80/20, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =6.879 min, t (minor) = 22.645 min, ee = 98%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =5.285 min, t (minor) = 9.705 min, ee = 99%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =8.792 min, t (major) = 10.739 min, ee = 98%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 95/05, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =26.065 min, t (major) = 28.952 min, ee = 97%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =9.185 min, t (major) = 16.112 min, ee = 97%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 90/10, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =7.519 min, t (minor) = 8.092 min, ee = 97%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =11.279 min, t (minor) = 13.519 min, ee = 99%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 98/02, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =38.425 min, t (major) = 42.452 min, ee = 97%.





Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =13.772 min, t (minor) = 21.719 min, ee = 98%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =11.839 min, t (major) = 12.679 min, ee = 98%.


Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =12.525 min, t (minor) = 22.972 min, ee = 99%.



Chiral HPLC chromatographic analysis of  ${\bf 30}$ 

Condition: Daicel Chiralcel AS-H, *n*-hexane/*i*-PrOH = 90/10, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =7.879 min, t (minor) = 11.565 min, ee = 99%.



Chiral HPLC chromatographic analysis of  ${\bf 31}$ 

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 80/20, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =6.365 min, t (minor) = 6.739 min, ee = 99%.



Chiral HPLC chromatographic analysis of  ${\bf 32}$ 

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =9.899 min, t (major) = 11.185 min, ee = 99%.



S112

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =13.272 min, t (major) = 14.252 min, ee = 98%.



Chiral HPLC chromatographic analysis of  ${\bf 34}$ 

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =13.172 min, t (major) = 25.485 min, ee = 97%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =9.919 min, t (major) = 11.079 min, ee = 99%.



Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =12.399 min, t (minor) = 13.739 min, ee = 98%.





Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =13.992 min, t (minor) = 17.232 min, ee = 97%.



## Chiral HPLC chromatographic analysis of ${\bf 41}$

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (major) =15.545 min, t (minor) = 18.132 min, ee = 99%.



Chiral HPLC chromatographic analysis of cyclohexyl(phenyl)phosphine oxide:

Condition: Daicel Chiralcel AD-H, *n*-hexane/*i*-PrOH = 85/15, UV = 254 nm, flow rate: 1.0 mL/min, retention time: t (minor) =9.605 min, t (major) = 10.992 min, ee = 98%.



S119